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1. Introduction 
Breast carcinoma is the most common malignancy that affects women and is 
also the most important cause of cancer-related death (1). The incidence varies 
substantially but has been increasing even in the regions that recently reported low rates 
of the disease (1). 
 
1.1 Apocrine carcinoma of the breast 
Invasive carcinoma of the breast comprises a heterogeneous group of tumors 
showing diverse morphologic, molecular, and clinical features (2, 3). Invasive ductal 
carcinoma of no special type (NST) is the most common type, constituting up to 75% of 
all breast malignancies (2, 4). The remaining 25% includes various special types with 
18 different subtypes including apocrine carcinoma of the breast. 
The histopathologic characteristics of breast cancers tend to be associated with 
distinct arrays of genetic changes, providing evidence for genotypic–phenotypic 
correlations between morphologic patterns and molecular changes in special types of 
breast carcinomas (5). 
The initial microarray-based expression profile studies on breast carcinomas of 
NST revealed the existence of five molecular subtypes including luminal types (A and 
B), basal-like, ERBB2/HER-2-overexpressing and normal-like type (6, 7). Luminal 
subtypes A and B are estrogen receptor (ER) positive and share expression markers with 
the luminal epithelial layer of cells whereas basal-like carcinomas share expression 
markers with the underlying basal (myoepithelial) layer of normal breast ducts and are 
ER negative. The ERBB2 subtype is associated with expression of genes co-amplified 
with ERBB2/HER-2/neu (encoding Her-2/neu protein), and the normal-like subtype 
shares expression patterns with normal breast tissue (6, 7). 
Apocrine differentiation (metaplasia) is commonly seen in the breast pathology, 
particularly in the context of fibrocystic breast disease (8-11) although it may be seen in 
association with other benign and malignant conditions (12). The benign breast lesions 
with apocrine morphology include papillary apocrine changes, apocrine cysts, apocrine 
adenosis (sclerosing adenosis with apocrine metaplasia), and apocrine adenoma (2, 8, 
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13). Malignant apocrine lesions of the breast include apocrine ductal carcinoma in situ 
and invasive apocrine carcinoma (8).  
Apocrine carcinoma of the breast, defined as breast tumors composed of 
epithelium with apocrine differentiation in more than 90% of the tumor cell population, 
represents a rare subtype, constituting less than 5% of all breast cancers (4, 14, 15). 
Apocrine differentiation is defined by the presence of large cells with prominent 
eosinophilic, flocculent cytoplasm, with sharply defined cell borders, and with large 
nuclei containing prominent macronucleoli. The majority of cases of apocrine 
carcinomas tend to be sporadic although an association with Cowden syndrome caused 
by germline mutations of the tumor suppressor gene PTEN has recently been reported 
(16). 
A characteristic steroid receptor expression profile defines apocrine carcinomas 
as consistently estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, 
and androgen receptor (AR)-positive (12, 17-20). Although AR expression has been 
variably observed in up to 60-70% breast carcinomas (21-23), consistent AR expression 
tends to be a feature of apocrine breast lesions including invasive apocrine carcinomas 
(12, 17, 18, 24-30). Moreover, recently published gene expression microarray studies 
defined a characteristic “molecular apocrine” gene expression profile found in apocrine 
carcinomas (31-35). These studies showed apocrine tumors to be different from 
common luminal and basal cell breast carcinoma subtypes (31-34) and showed that they 
are characterized by increased androgen receptor (AR) signaling along with increased 
HER-2/neu gene signaling (31, 34). Differentially expressed genes also included the 
following genes: SPDEF, FOXA1, XBP1, CYB5, TFF3, NAT1, APOD, and ALCAM 
(20). These observations were later confirmed by gene expression meta-analysis that 
revealed the existence of molecular apocrine group characterized by increased AR 
signaling pathway and interactions between AR and the erbB receptors family (34). 
Androgen receptor is an active player in several important signaling pathways in breast 
carcinogenesis (36). Studies using apocrine cell line models (MDA-MB-453 and Sum-
190) demonstrated the existence of a functionally significant cross-talk between AR and 
HER-2/neu pathways through ERK1/2 in ER negative breast carcinomas (37, 38). 
Specifically, AR regulates ERK phosphorylation and kinase activity. Furthermore, AR 
activation is associated with the overexpression of ERK signaling targets including 
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phospho-Elk-1 and c-Fos (38). This cross-talk affects cell proliferation and apoptosis 
and could have a significant therapeutic impact (37, 39, 40). Also, activation of the 
ERBB2-PI3K-AKT signaling pathway caused by loss of PTEN gene function may 
contribute to development of breast carcinomas with apocrine features (16, 41). 
Androgen receptor also mediates ligand-dependent activation of Wnt signaling pathway 
(36) while specific targeting of AR, Wnt or HER-2 signaling impairs androgen-
stimulated tumor cell growth (36). Apocrine carcinomas frequently express an AR-
producing enzyme 5-α reductase which converts testosterone to a potent 
dihydrotestosterone (29). 
Apocrine carcinomas typically exhibit a strong cytoplasmic expression of gross 
cystic disease fluid protein-15 (GCDFP-15), an apocrine-specific marker, regulated by 
AR and other proteins involved in lipid metabolism (8, 15). At proteomic level, when 
compared with benign apocrine lesions, apocrine carcinomas also are characterized by 
increased S100A9 and S100A7 and decreased expression of 15-hydroxy-prostaglandin 
dehydrogenase (15-PGDH) and hydroxymethyl-glutaryl coenzyme A (HMG-CoA) 
reductase (15). 
Although apocrine carcinoma exhibits distinctive histopathologic and molecular 
features, the lack of standardized diagnostic criteria has produced controversial and 
heterogeneous results in the scientific literature in terms of its immunohistochemical 
profile and molecular classification (15, 42-44). 
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1.2 The erbB (HER, human epidermal growth factor receptor) family  
The erbB (HER, human epidermal growth factor receptor) family is composed 
of four homologous transmembrane receptors involved in growth factor cellular 
signaling (45). This family includes EGFR (HER-1, ErbB1), ErbB2 (HER-2/neu), 
ErbB3 (HER-3), and ErbB4 (HER-4) (46).  
EGFR (or HER-1) and HER-2/neu genes are of particular importance in breast cancer 
pathogenesis as their activation and co-expression are associated with an aggressive 
clinical course and a poor outcome (46). Both proteins can be targeted by specific 
therapeutic modalities (monoclonal antibodies and tyrosine kinase inhibitors).  
 
1.2.1 Epidermal growth factor receptor (EGFR/HER-1)  
EGFR is a 170 kD transmembrane receptor encoded by the human HER1 gene 
which maps to 7p11.2-p12 (47). The EGFR protein has an extracellular ligand binding 
domain, a transmembrane region, and an intracellular domain with intrinsic protein-
tyrosine kinase activity and multiple autophosphorylation sites clustered at the C-
terminal tail (46, 47). The extracellular domain of EGFR consists of four subdomains 
(I–IV). Subdomains I and III (also called L1 and L2) have a beta helical fold and are 
involved in ligand binding (48). 
 EGFR is homologous to other members of the EGF receptor/erbB family 
including HER-2/erbB2 or neu, HER-3/erbB3 and HER-4/erbB4/. All four members can 
form homo- and heterodimers (46, 47). EGFR-specific ligands include epidermal 
growth factor [EGF], transforming growth factor-α [TGF-α], and amphiregulin (47, 48) 
all of which may induce distinct biological responses and patterns related to EGFR 
signaling (46). EGFR activates several key signaling pathways including PI3K/AKT 
signaling pathway, Ras/Raf1/Mitogen-activated protein kinase signaling pathway, 
SRC/NF-κB, catenin/cytoskeleton, and PAK-1/rac signaling pathway and plays a 
pivotal role in proliferation and survival of breast epithelium (47). 
EGFR protein expression has been observed in a variety of normal cells 
including many epithelial cell types and tumors derived from them. Non-epithelial cell 
types that may express EGFR include smooth muscle, fibroblasts, endothelial cells, 
sympathetic ganglia, and peripheral nerve fibers (49). 
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Dysregulation of EGFR has been described in various human malignancies 
including breast cancer (46, 47). Dysregulation can occur via increased receptor 
activation (e.g. binding of ligands: EGFs, TGF-α or amphiregulin), activating mutations, 
decreased activity of phosphatases that inhibit tyrosine kinase domain of EGFR, 
abnormal heterodimerization and cross-talk with various molecules including other 
ErbB receptors, cell adhesion molecules, cytokine receptors, and ion channels (46, 47). 
A particularly important type of EGFR activation is EGFRvIII mutation frequently 
encountered in glioblastoma multiforme (48). The EGFRvIII mutant receptor contains 
an in-frame deletion of exons 2-7 from the extracellular region resulting in the 145 kD 
constitutively active EGFR protein (48). EGFRvIII has also been described in breast 
carcinomas, particularly in those exhibiting stem cell features (CD44
+
/CD24
-
 phenotype 
or ALDH positivity) (50). 
EGFR status has been extensively studied in breast pathology including breast 
cancer (46). Breast cancer cells tend to over-express EGFR protein in a range between 
18-35% whereas EGFR gene amplification has been only observed in ~6% of breast 
carcinomas (51). Activating mutations of the EGFR gene appear to be an exceptionally 
rare phenomenon in breast cancer with only single reports harboring EGFR gene 
mutation (52-55). 
EGFR protein expression is particularly common (~70%) in a subset of breast 
carcinomas defined as triple-negative carcinomas with basal-like characteristics (“basal-
like”) and BRCA-1-mutated breast carcinomas (47, 56-58). Both groups exhibit a 
characteristic triple-negative immunophenotype (ER-/PR-/Her-2-/) with expression of 
one of basal cell markers including basal cytokeratins (CK5/6, CK14, CK17) and/or 
EGFR protein (3, 59, 60). Some researchers proposed EGFR protein to be specific for 
triple-negative breast carcinomas (61) serving as a surrogate marker for a “basal-like” 
phenotype (62). Nevertheless, the “basal-like” group also rarely exhibits EGFR gene 
alterations (mutations or gene amplification) (47, 57, 58, 63).  
EGFR status has not been extensively studied in apocrine carcinoma of the 
breast (34, 42, 64). Apocrine metaplasia of the breast does not tend to over-express 
EGFR protein (65). A study of Bhargava et al (2010) based on a small subset of breast 
tumors with apocrine differentiation, indicated a preponderance of these tumors to 
overexpress EGFR protein (64). MDA-MB-453 breast cancer cell line, proposed to have 
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apocrine features, also tends to over-express EGFR protein without underlying EGFR 
gene amplification (66). Based on the analysis of EGFR phosphorylation sites, Koletsa 
et al (2010) also reported that HER-2-positive breast carcinomas tend to have EGFR 
protein activated but without EGFR gene amplification (67). 
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1.2.2 HER-2/neu gene 
HER-2/neu is a proto-oncogene located on chromosome 17 (17q21-22) (68), 
(Figure 1). Its structure is similar to that of EGFR. HER-2/neu gene encodes a 185 kD 
tyrosine-kinase receptor located on the surface of the breast epithelial cells (68, 69). 
Her-2/neu receptor also closely interacts with other erbB family members who act as 
receptors for various ligands (EGFs, TGF-α, amphiregulin) (48, 70-72). Her-2/neu 
receptor has no cognate ligands (48). It exerts effects through heterodimerizations 
among which HER-2/HER-3 heterodimers appear to be the most potent (48). This dimer 
has a high propensity to activate PI3K/AKT and Ras/Raf1/Mitogen-activated protein 
kinase signaling pathway both of which are critically important for cell survival and 
proliferation (48). Besides, HER-2/HER-3 dimers can evade downregulation 
mechanisms leading to prolonged survival (48). 
 HER-2/neu status analysis is mandatory in all breast carcinomas as an 
appropriate therapeutic strategy to target this oncoprotein has been developed 
(Trastuzumab (Herceptin ®; Genentech, South San Francisco, CA, USA) (73-77). 
Trastuzumab represents a recombinant humanized monoclonal antibody (rhumAb 4D5) 
targeted against an extracellular domain of HER-2/neu gene (78). Recently, several 
novel anti-HER-2 based drugs including monoclonal antibodies and tyrosine kinase 
inhibitors have also demonstrated a promising activity in the treatment of HER-2 
positive breast cancer (79).  
The protein expression is usually determined by immunohistochemistry (77). 
Several commercially available antibodies have been validated and routinely used 
including: A0485 (HercepTest, Rabbit polyclonal, DAKO), CB11 (Mouse monoclonal, 
Ventana), SP3 (Rabbit monoclonal, NeoMarkers), TAB250 (Mouse monoclonal, 
Invitrogen), and 4D5 (Mouse monoclonal, Genentech) (77). 
The primary mechanism of Her-2/neu overexpression in breast cancer is 
amplification of the HER-2/neu gene (69). The rate of HER-2/neu gene amplification is 
now estimated to be approximately 15% of all breast cancers which is much lower in 
comparison with the rates reported in the historic studies (25-30%) (69, 80-82). The 
HER-2/neu gene amplification correlates well with overexpression of Her-2/neu protein 
measured by immunohistochemistry. 
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Amplification of the HER-2/neu gene is typically detected by fluorescence in 
situ hybridization (FISH), although other in situ hybridization methods are now 
increasingly used (chromogenic [CISH] and silver in situ hybridization [SISH]) as well 
as multiplex ligation-dependent probe amplification [MLPA]) and comparative genomic 
hybridization (CGH) (83-84). Only two of the abovementioned methods (FISH and 
CISH) have been however approved by the US American Food and Drug 
Administration for routine diagnostics (83). 
For FISH analysis, three different kits have been approved by the US Food and 
Drug Administration: 1) PathVysion (Abbott Laboratories, Abbott Park, Ill), 2) 
INFORM (Ventana Medical Systems, Tucson, AZ), or 3) PharmDx (DAKO, Glostrup, 
Denmark). The INFORM kit evaluates only the HER-2/neu gene copy number, and 
results are based on the absolute HER-2/neu signal count. The PathVysion and 
PHarmDx kits employ two probes, a HER-2/neu probe and a chromosome 17 
centromere enumeration probe (CEP17) hybridization control probe, and results are 
based on the HER-2/CEP17 ratio.  
Current American Society of Clinical Oncology/College of American 
Pathologists (ASCO/CAP) guidelines define HER-2-positive tumors as those with an 
average HER-2/neu gene copy number of > 6 gene copies per nucleus (for single probe 
assays) or as a HER-2/CEP17 ratio of > 2.2 (for double probe assays) (73). Typically, 
similar conclusions are obtained with either the absolute HER-2/neu signal count or the 
HER-2/CEP17 ratio (85), but discrepancies can occur in cancers with increased CEP17 
copy number (≥3 copies per tumor cell). For example, tumors with increased CEP17 
copy number and slightly increased HER-2/neu copy number may be considered 
amplified by single probe assays but unamplified by double probe assays. It is estimated 
that this occurs in 2-9% of breast cancers (86-87). However, the reported frequency of 
CEP17 copy number alteration in breast cancer varies, depending on the study 
population, selection criteria, and the definition of chromosome 17 polysomy (CEP17) 
(77, 88-93). 
 In the literature, it is commonly assumed that an increase in CEP17 copy 
number is due to polysomy 17, and these terms have been used interchangeably. 
However, it is important to recognize that an increase in CEP17 signals does not 
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necessarily represent a true polysomy (i.e. gain of the entire chromosome), but rather 
may represent a focal pericentromeric gain or a partial polysomy (92-95). 
 
 
 
Figure 1. Schematic representation of chromosome 17 with important genes including 
HER-2/neu gene at 17q21-22  
(From: Zhang W et al, Int J Mol Sci 2011;12:5672-5683). [Open Access Journal] 
 10 
1.2.3 HER-3 gene 
The HER-3 gene is located on chromosome 12q13 (96). It encodes protein 
receptor that binds to the splice variants of neuregulins (NRG-1 and NRG-2) (96).  
HER-3 activation is closely related to the formation of heterodimers with other 
erbB/HER family members as HER-3 receptor has no intrinsic kinase activity (96). Of 
particular importance is the HER-2/HER-3 heterodimer complex that induces a 
significant mitogenic activity in breast cancer (96). 
HER-3 protein overexpression has been observed in approximately 30% of all 
breast carcinomas with contradictory results in regards to its prognostic significance 
(96). 
HER-3 appears to be involved in apocrine carcinoma pathogenesis as AR 
induces its expression through close interaction with HER-2/neu resulting in a positive 
feedback loop between AR and HER-2/neu (9, 36). This mechanism involves Wnt 
signaling activation via WNT7B leading to translocation of β-catenin to nucleus to help 
AR transactivate the HER-3 promoter region (9, 36). 
 
1.2.4 HER-4 gene 
The HER-4 gene is located on chromosome 2q33.3-34. It encodes protein that 
can be activated by both NRGs and various ligands of the EGF family (96). Four 
different isoforms of HER-4 receptor have been isolated. 
In contrast to other erbB family members, it induces antiproliferative and pro-apoptotic 
effects in breast cancer cells, mainly antagonizing HER-2 signaling activity (96). 
HER-4 overexpression has been observed in approximately 50% of breast 
carcinomas and was associated with a favorable outcome (96). 
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2. Hypothesis and Aims 
Basic hypothesis of the proposal is that cyto-morphologically defined invasive 
apocrine carcinomas are not a homogenous cancer subtype. Additional molecular 
investigations are necessary to define apocrine phenotype, and steroid receptor 
expression profile (immunohistochemistry for estrogen receptor, progesterone receptor, 
and androgen receptor) is necessary to accurately define this mammary carcinoma 
subtype. This could result in a sub-classification of this morphologic category into pure 
apocrine and apocrine-like carcinomas. Importantly, this reclassification can impact a 
commonly observed association between apocrine breast carcinoma and expression of 
EGFR and Her-2/neu proteins.  
We hypothesize that the primary mechanism of Her-2/neu protein over-
expression in apocrine carcinomas is due to the underlying HER-2/neu gene 
amplification while EGFR gene amplifications are uncommon. 
 
The aims of this study are: 
 
1. To refine a subgroup of invasive breast carcinomas with apocrine morphology 
on the basis of characteristic steroid receptor profile (Estrogen Receptor negative, 
Progesterone Receptor negative, and Androgen Receptor positive). 
2. To explore the status of tyrosine kinase receptors epidermal growth factor 
receptor (EGFR or HER-1) and human epidermal receptor (HER-2/neu) using 
immunohistochemistry (protein expression) and fluorescent in-situ hybridization (gene 
copy number).  
3. To explore a possible impact of polysomy of chromosomes 7 and 17 on the test 
interpretation and the status of EGFR and Her-2/neu protein expression. 
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3. Materials and Methods 
3.1 Specimens 
The formalin fixed paraffin-embedded (FFPE) tumor samples were obtained 
from 55 female patients with invasive apocrine carcinomas (52 surgical and 3 core 
biopsy specimens). Routinely stained hematoxylin and eosin (H&E) tumor sections 
were re-examined and the diagnoses confirmed. The cases were retrieved from the files 
of Creighton University Medical Center (Omaha, NE, USA), Kansas University 
Medical Center (Kansas City, KS, USA), Thomas Jefferson University Hospital 
(Philadelphia, PA, USA), The University of Texas Medical Branch (Galveston, TX, 
USA), and Clinical Center of the University of Sarajevo (Sarajevo, Bosnia and 
Herzegovina). 
The Nottingham histologic grading system was applied for the tumor grading (97, 98). 
An extended cohort of 72 patients whose breast cancers had greater than or 
equal to three Chromosome Enumeration Probe 17 (CEP17) signals per nucleus on 
average by fluorescent in situ hybridization (FISH) was used for further evaluation of 
impact of polysomy of chromosome 17 (CEP17 polysomy) on HER-2/neu gene copy 
number/Her-2 protein interpretation. These cases were retrieved from the pathology 
reports from Creighton Medical Laboratories [CML] (Creighton University, Omaha, 
NE, USA). The cohort represented approximately 12% of all HER2-tested cases in the 
period 2003-2007.  
Institutional review board of Creighton University approved the study. 
 
3.2 Immunohistochemistry (IHC)  
Immunohistochemical assays for estrogen receptor-alpha (ERα; clone 6F11, 
Ventana Medical Systems, Inc. Tucson, AZ), progesterone receptor (PR; clone 16, 
Ventana Medical Systems, Inc. Tucson, AZ), androgen receptor (AR; Clone AR441, 
DakoCytomation, Inc. Carpinteria, CA), EGFR (DAKO EGFR PharmDX diagnostic 
kit; DakoCytomation, Inc. Carpinteria, CA), and Her-2/neu (Clone CB11, Ventana 
Medical Systems, Inc. Tucson, AZ) expression were performed on FFPE tissue sections 
using the commercially available detection kits and automated staining procedures. 
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The tumor was regarded as positive for ER and PR if more than 5% of the cells 
showed nuclear staining, while a 10% cutoff was applied for AR staining (20, 99, 100). 
Her-2/neu protein expression results were scored according to the American 
Society of Clinical Oncology/College of American Pathologists Guideline 
Recommendations (73). Briefly, cases showing no membrane immunostaining or 
membrane immunostaining in less than 10% tumor cells were scored 0+, cases with 
weak and incomplete membrane staining in more than 10% of tumor cells were scored 
1+, cases with complete membrane staining that was either non-uniform or weak in 
intensity but with obvious circumferential distribution in more than 10% of cells were 
scored 2+ and cases with strong membrane staining in more than 30% tumor cells were 
scored 3+ (73).  
EGFR protein expression was scored according to the scoring guidelines for 
Her-2/neu protein (101). 
 
3.3 Automated Cell Imaging System (ACIS)  
Quantitative image analysis was performed using ACIS (ChromaVision Medical 
Systems, Inc., San Juan Capistrano, CA). ACIS was used for measuring the percentage 
of cells with the nuclear staining for ER, PR, and AR, and the extent and the intensity of 
the membranous staining of EGFR and Her-2/neu proteins. The images were reviewed 
and tumor-rich areas of the sections were selected for the analysis. The ACIS scoring 
system for Her-2/neu protein was as follows: score <1.0 (negative, equivalent to 1+), 
score 1.0-2.4 (borderline, 2+), and score ≥2.4 (positive, 3+). 
 
3.4 FISH analysis 
Fluorescent in-situ hybridization (FISH) was performed to evaluate copy 
number at EGFR and HER-2/neu loci. Chromosome enumeration probes CEP7 and 
CEP17 were used as positive controls and indicators of chromosome ploidy (Abbott 
Molecular Inc., Des Plaines, IL). Probe signals were enumerated in predominant tumor 
cell populations. At least thirty nuclei were scored per sample. A ratio of HER-2/CEP17 
> 2.2 was defined as gene amplification; a ratio 1.8-2.1 was interpreted as borderline, 
and a ratio < 1.8 was defined as negative. The same criteria were used for interpretation 
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of EGFR/CEP7 ratios. Equivocal FISH results (ratio of 1.8-2.2) were considered as 
negative for HER-2/neu and EGFR gene amplification, respectively (73). CEP7 and 17 
polysomy were defined as three or more CEP signals per cell (45, 102-104).  
Stromal cells and normal breast epithelial cells served as an internal control. 
 
3.5 Conventional Cytogenetics 
Cytogenetic analysis was performed on biopsy tissue of one pure apocrine 
carcinoma harboring HER-2/neu gene amplification and CEP17 polysomy. Culture 
initiation, maintenance and harvesting were done using standard methods (105). 
Chromosomes were G-banded using pancreatin and analyzed using a Cytovision image 
analysis system (Applied Imaging, Santa Clara, CA). 
 
3.6 SNP array karyotyping 
Single nucleotide polymorphism (SNP) array karyotyping was performed on 
four cases including two cases of apocrine carcinomas with HER-2/neu gene 
amplification and two cases of invasive ductal carcinomas (NST) exhibiting a 
borderline Her-2/neu score on IHC (score 2+) and CEP17 polysomy on FISH analysis.  
Following tumor enrichment via manual microdissection, DNA was obtained 
from 10 µm paraffin sections according to a previously described protocol for 
deparaffinization and DNA extraction (106). Samples were processed with the 250K 
Nsp Assay Kits (Affymetrix, Santa Clara, CA). Briefly, 1 μg of gDNA was digested 
with Nsp restriction enzyme, ligated to the adaptors, and amplified by PCR using a 
universal primer. After purification of PCR products with SNP Clean magnetic beads 
(Agencourt Biosciences, Beverly MA, USA), amplicons were quantified, fragmented, 
labeled, and hybridized to 250K Nsp arrays. After washing and staining, the arrays were 
scanned to generate CEL files for downstream analysis.  
Data acquired from the Affymetrix GeneChip Operating System v4.0 (GCOS) 
was analyzed using Affymetrix Gene-Chip Genotyping Analysis Software (GTYPE) 
4.1. Copy number analysis was performed with Copy Number Analyzer for Affymetrix 
GeneChip arrays (CNAG 3.0), as described before (107).  
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3.7 Statistical analysis 
 Where appropriate, chi-square test/Fisher’s exact test or non-parametric tests 
(Mann-Whitney U-Test) were used for comparisons of the groups. Spearman’s 
correlation rank was applied for the correlation between the variables. All statistical 
tests were 2-sided and P-values of less than 0.05 were considered significant. The 
statistical analysis was done with the Statistical Package for the Social Sciences version 
17.0 (SPSS Inc., Chicago, IL).  
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4. Results 
4.1 Clinico-pathologic characteristics of the apocrine carcinoma cohort 
All patients were females. Patients’ mean age was 62 years (range: 32-92 years). 
Routinely stained hematoxylin and eosin (H&E) tumor sections were re-examined and 
the diagnoses confirmed. Morphologically, all 55 cases fulfilled criteria for apocrine 
carcinoma and were characterized by large cells with prominent eosinophilic, flocculent 
cytoplasm, sharp cell borders, and large nuclei with prominent macronucleoli (Figure 
2A-B). 
Of the fifty-five cases 28 cases (50.9%) were histologic grade 3, 24 cases 
(43.6%) grade 2 and only three cases (5.4%) histologic grade 1. 
 
 
 
Figure 2A-B. Hematoxylin & eosin (HE) stained sections of two cases of breast 
carcinomas with similar apocrine morphology: (A): pure apocrine carcinoma (ER-/PR-
/AR+); (B): Apocrine-like carcinoma (ER+/PR-/+/AR+/-). 
 
4.1.1 Classification and steroid receptor profile of apocrine carcinomas 
Thirty-eight (69.1%) out of 55 cases fulfilled immunophenotypic diagnostic 
requirements for pure apocrine carcinoma (PAC): ER and PR negative, AR positive 
(Fig. 2A, 2C, 2E; Table 1). The 17 remaining cases (30.9%) were then termed 
‘apocrine-like’ carcinomas (ALC) because they lacked the specific apocrine 
immunophenotypic profile (Fig. 2B, 2D, 2F). These were further subcharacterized as: 
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ALC with ER+/AR- immunophenotype (3 cases), ALC with ER-/AR- 
immunophenotype (4 cases), and ALC with ER+/AR+ immunophenotype (10 cases) 
(Table 1). 
The mean tumor AR positivity was significantly higher in the PAC subgroup in 
comparison with the ALC AR+/ER+ subgroup (75.8% vs. 58.9%, p=0.037). PAC 
exhibited a diffuse and strong nuclear staining of androgen receptor (16/30 or 53.3% of 
PAC had a 100% cells expressing AR) (Figure 2E). In contrast, none of the 17 ALC 
cases exhibited such complete AR expression. 
 
 
 
 
Figure 2C-D: Immunohistochemistry (IHC) showing negative estrogen receptor 
expression in a case of pure apocrine carcinoma with a positive staining of normal 
epithelium (C), and strongly positive expression in an apocrine-like breast carcinoma 
(D).  
 
C D 
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Figure 2E-F: IHC showing diffusely positive androgen receptor expression in a case of 
a pure apocrine carcinoma (E), and negative expression in an apocrine-like carcinoma 
(F).  
 
 
 
 
Figure 2G-H: IHC showing strong membrane expression of EGFR protein (score 3+) 
in a case of pure apocrine carcinoma (G), and 3+ membrane expression of Her-2/neu 
protein in a case of apocrine-like breast carcinoma (H). 
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4.1.2 HER-2/neu expression in apocrine carcinomas 
Her-2/neu protein overexpression (score 3+) was observed in 53.7% of the cases 
in the entire cohort without significant difference between the PAC and ALC groups 
(56.8% vs. 47.1%, p=0.81) (Fig. 2G). 
HER-2/neu gene amplification was detected in 28 of 54 tested cases (51.9%) 
without significant differences between the PAC and the ALC group (54% vs. 46%, 
p=0.42) (Fig. 3A; Fig. 5A-B). The average HER-2/neu gene signal number per cell 
ranged from 1.67-50 (mean: 9.57). HER-2/neu FISH results were concordant with Her-
2/neu immunohistochemistry results in 49 of 53 available cases (92.5%). Four positive 
immunohistochemistry Her-2/neu results (score 3+) were discordant with HER-2/neu 
FISH results (negative for HER-2/neu gene amplification). Three of eight cases (37.5%) 
with equivocal immunohistochemistry (score 2+) had HER-2/neu gene amplification.  
Six samples had fewer HER-2/neu signals per cell than signals for chromosome 
17 centromere (ratio: 0.72-0.99). One of these cases had a Her-2/neu protein 
overexpression. 
CEP17 polysomy (defined as three or more copies of CEP17 signals per 
nucleus) was observed in 10 PACs (32.3%) and 8 ALCs (50%). CEP17 polysomy was 
seen without HER-2/neu gene amplification in 8 cases (Fig. 3C) and with HER-2/neu 
gene amplification in 10 cases. The CEP17 polysomy rate was low: mean 3.55 CEP17 
signals; (range: 3.0-6.0). Two PACs and three ALCs (5/8, 62.5%) with CEP17 
polysomy alone, had Her-2/neu protein expression scores of 2-3+ by IHC. 
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Figure 3. Pure apocrine carcinomas showing HER-2/neu gene amplification (A); EGFR 
gene amplification (B); Polysomy 17 (CEP17) without HER-2/neu gene amplification in 
a case of an apocrine-like carcinoma [average: 6.06 signals per cell] (C), and polysomy 
7 (CEP7) without EGFR gene amplification [average: 3.62 signals per cell] (D). 
 
4.1.3 EGFR expression in apocrine carcinomas 
Thirty four out of 55 (61.9%) cases expressed EGFR protein (scores 1-3+). A 
significantly higher proportion of PACs was positive for EGFR protein in comparison 
with the ALC subgroups (76.3% vs. 29.4%, p=0.006) (Fig. 2H). A diffuse (more than 
50% of positive cells) and strong (intensity scores 2-3+) EGFR expression, was seen in 
20/29 (68.9%) of the PAC-positive cases and 5/5 (100%) of the ALC-positive cases. 
EGFR gene amplification was a rare event, present only in three (2 PAC and one ALC 
tumors) of 44 studied cases (6.8%) (Fig. 3B). All three cases exhibited EGFR protein 
overexpression. The average EGFR gene signal number per cell ranged from 1.6-20 
(mean: 5.76).  
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Polysomy of chromosome 7 (CEP7 polysomy) (defined as three or more copies 
of CEP7 signals per nucleus) was detected in 20/33 PACs (60.6%) and 3/11 ALCs 
(27.3%) either alone (21 cases) (Fig. 3D) or in association with the EGFR gene 
amplification (2 cases). CEP7 polysomy was more frequently observed in the PAC 
subgroup compared with the ALC subgroup (p=0.083). Overall, the level of CEP7 
polysomy was low (mean: 4.09, range: 3.0-7.06). A weak positive correlation between 
polysomy 7 and the EGFR protein expression was also present (p=0.025, r=.326). 
 
 
Table 1. Status of EGFR and Her-2/neu protein expression and gene amplification in 
pure apocrine carcinomas (PAC) and subgroups of apocrine-like carcinomas (ALC). 
 
 
Category 
Androgen 
receptor (AR)
1
 
Her-2/neu 
(IHC)
2
 
HER-2/neu 
(FISH)
3
 
EGFR 
(IHC)
4
 
EGFR 
(FISH)
3
 
 
PAC 
 
38/38 (100%) 
Mean: 75.76 
Range: 10-100 
 
21/37 
(56.8%) 
 
20/37 (54%) 
 
29/38 
(76.3%) 
 
2/35 (5.7%) 
 
ALC (ER+, 
AR+) 
10/10 (100%)  
Mean: 58.93 
Range: 15-90 
 
2/10 (20%) 
 
4/10 (40%) 
 
3/10 (30%) 
 
1/7 (14.3%) 
 
ALC (ER+, 
AR-) 
 
0/3 (0%) 
 
3/3 (100%) 
 
3/3 (100%) 
 
0/3 (0%) 
 
0/1 (0%) 
 
ALC (ER-, 
AR-) 
 
0/4 (0%) 
 
3/4 (75%) 
 
1/4 (25%) 
 
2/4 (50%) 
 
0/4 (0%) 
1 
Positivity defined if more than 10% cells exhibited nuclear staining 
2 
Defined by the 3+ score by IHC 
3 
Defined by the gene to centromere ratio > 2.2 
4
 Scores 1-3+ by IHC 
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4.1.4 Chromosomal analysis using conventional cytogenetics and SNP array 
assay 
Corroborative genetic evidence for FISH results (HER-2/neu gene amplification, 
CEP7 and CEP17 polysomy) was obtained in three cases which were further studied by 
conventional cytogenetics and SNP arrays. One case of PAC [displaying polysomy 7 
(4.37 CEP7 copies on average) and HER-2/neu gene amplification (HER-2/CEP17 ratio: 
20/2.1 = 9.5], was analyzed by conventional cytogenetic analysis and showed complex 
cytogenetic alterations (Fig. 4) described as: 65-69,XXX,+i(1)(q10),-2,-
3,add(3)(p12),add(6)(q27),+7,-8,-10,-11,add(11) (p15),add(11)(q23),-12,-
13,add(14)(p11.2),-15,+16,-17,-18,-19,dd(19)(q13.4),-20,-21,-22, 
+mar1,+mar2,+mar3,+mar4,+mar5,+5-8mar[5]/130-138, idemx2[2]/46,XX[13]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Conventional cytogenetics performed on a case of pure apocrine carcinoma 
revealed complex cytogenetic alterations including gains of chromosome 7 and loss of 
chromosome 17. 
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Another two cases [(one PAC and one ALC, both with HER-2/neu gene 
amplification] were studied by SNP arrays which confirmed FISH results and further 
revealed amplification of CEP17 without polysomy of chromosome 17 in the first one 
(Sample GLID09_0048) whereas the second one (Sample GLID09_0050) had co-
amplification of HER-2/neu and TOP2A along with a gain of CEP17 (Fig. 6). 
 
 
Figure 5A-B. Metaphase FISH analysis of the apocrine carcinoma showing 
amplification of the HER-2/neu gene (red).  
One of the larger marker chromosomes contains homogeneously staining region (hsr) of 
HER-2/neu gene amplification. 
(Courtesy of Dr. Julia Bridge, University of Nebraska Medical Center, Omaha, NE) 
 
A 
B 
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Figure 6. SNP array karyotypes of chromosome 17 for two samples with amplification 
of HER-2/neu. The first one (Sample GLID09_0048) had amplification of both CEP17 
and HER-2/neu amplification without polysomy 17 whereas the second one (Sample 
GLID09_0050) had co-amplification of HER-2/neu and TOP2A genes along with a gain 
of CEP17.  
Plots are as follows: A) The raw log2ratio of tumor/normal for each probe on the array; 
B) Smoothing average over 10 probes; C) Hidden Markov Model of copy number with 
aqua = 1, yellow = 2, pink = 3, pink-red = 4, red-pink = 5, and red >5. 
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4.1.5 Molecular subclassification of carcinomas with apocrine morphology 
We found a statistically significant inverse correlation between EGFR and Her-
2/neu expression in the PAC subgroup (p=0.006, r=-.499). Therefore, 20/37 (54%) PAC 
cases can be classified as HER-2-overexpressing whereas the remaining 17 cases (46%) 
as triple-negative breast carcinomas. Sixteen out of 17 triple-negative PACs (94.1%) 
overexpressed EGFR and would accordingly be classified as basal-like breast 
carcinomas (62) (Table 2). None of PACs fulfilled the criteria for luminal tumors (6, 7, 
62). 
In contrast, a large proportion of ALCs belonged to the luminal group (13/17 cases, 
76.5%). Only three cases (17.6%) could be classified as triple-negative breast 
carcinomas and one case only as HER-2-overexpressing breast carcinoma. 
 
 
Table 2. Molecular subclassification of apocrine carcinoma subtypes 
 
Apocrine carcinoma subtype Molecular phenotype 
 
Pure apocrine carcinoma 
HER-2 (20/37, 54%)
1
 
Triple-negative (17/37, 46%)  
- Basal-like breast carcinoma* 
(16/17, 94.1%) 
 
 
Apocrine-like carcinoma 
Luminal (13/17, 76.5%) 
Triple-negative (3/17, 17.6%)  
- Basal-like breast carcinoma
2
 (2/3, 
66.6%) 
HER-2 (1/17, 5.9%) 
1 
HER-2/neu gene amplification was used as a criterion. 
2 
Based on EGFR protein expression (62). 
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4.2 Clinico-pathologic characteristics of the cohort with CEP17 
polysomy 
Based on the frequently observed CEP17 polysomy in apocrine carcinomas of 
the breast, we further investigated our databases for the frequency of CEP17 polysomy 
and its impact on HER-2/neu status and interpretation. We identified 72 such cases 
which represented approximately 12% of all HER2-tested cases in the period 2003-
2007. 
All but two patients were women. The patient’s age ranged between 34 and 99 
years (mean 58.3 years). The study included 68 primary and 4 metastatic breast 
carcinomas. The majority of the cases were invasive ductal carcinomas of no special 
type (65 cases, 90.3%). The remaining cases included three mucinous carcinomas 
(4.2%), one case of invasive lobular carcinoma (1.4%), one case of mammary Paget’s 
disease in association with invasive ductal carcinoma (1.4%) and two cases of ductal 
carcinoma in situ (DCIS, 2.8%). 
 
 
 
Figure 7. Euler diagram showing sub-distribution of cases of breast carcinomas with 
CEP17 polysomy. 
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4.2.1 FISH results and interpretation 
The HER-2/neu gene and CEP17 copy number, HER-2/CEP17 ratio, and Her-
2/neu protein expression results are summarized in Table 3 and Figure 7 (Euler 
diagram). Average CEP17 copy number for the cohort was 4.5 and ranged from 3.0 to 
10.4 (Figure 8). HER-2/neu gene amplification as defined as the ratio of HER-2/CEP17 
>2.2, was identified in twenty-one cases (29.2%). All these cases had >6 HER-2/neu 
signals per nucleus. More than 6 HER-2/neu copies per nucleus were observed in an 
additional 12 cases without an increased HER-2/CEP17 ratio, for a total of 33 cases 
(45.8% of all cases); using the criterion of >6 HER-2/neu signals per nucleus as positive 
for amplification, these 33 cases would be categorized as HER-2 “amplified.” These 
findings, therefore, demonstrate that discrepant interpretation of gene amplification 
status was detected in 12 cases (36.4%) when the number of CEP17 copies was taken 
into the account. Of these 12 cases, Her-2/neu protein immunohistochemistry was 
available for 10 cases: 3 cases had Her-2/neu over-expression (score 3+), 6 cases had 
borderline score (2+) whereas one case was negative (score 1+). 
Interestingly, HER-2/CEP17 ratios smaller than 1.0 were observed in nine cases 
(12.5%), of which three cases (4%) had HER-2/CEP17 ratio ≤ 0.7. One of these cases 
had a ratio of less than 0.5 (1.71 HER-2/neu signals and 4.06 CEP17 signals, ratio = 
0.42), indicating that amplification of the centromeric region may not be accompanied 
by amplification of the HER-2/neu gene region in some cases. 
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Figure 8. Dual color fluorescent in-situ hybridization assay showing multiple copies of 
the CEP17 (green) and the HER-2/neu gene (red). 
 
 
Table 3. Results of the immunohistochemistry and fluorescent in situ hybridization in a 
cohort of 72 cases with CEP17 polysomy 
 
HER-2/neu gene copy number HER-2/CEP17 ratio 
>6 copies 
≤ 6 copies 
33 (45.8%) 
39 (54.2%) 
>2.2  
<2.2  
21 (29.2%) 
51 (70.8%) 
CEP17 copy number Her-2/neu protein expression 
> 6 copies               
≤ 6 copies               
9 (12.5%) 
63 (87.5%) 
≥2.4 (score 3+)  
<2.4 (score 0-2+)                   
22 (36.1%)                        
39 (63.9%) 
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4.2.2 SNP array karyotyping and interpretation 
Cytogenomic arrays provide high resolution, genome-wide copy number 
information. Affymetrix 250K Nsp mapping arrays contain 250,000 probes genome-
wide, including 4,854 probes on chromosome 17 and was used in 2 cases of invasive 
ductal carcinomas (NST) to further investigate the relationship between CEP17, HER-
2/neu gene and other loci on chromosome 17. SNP array analysis of the first case with a 
FISH HER-2/CEP17 ratio of 0.7 (2.3/3.3), revealed that copy number variability 
occurring along chromosome 17 may be undetected when using one or two FISH probes 
to determine chromosome 17 copy number. In this case, the copy number at the CEP17 
locus is 3, while that at the HER-2/neu locus is 2, generating a ratio of 0.67 (Figure 9). 
Another case with similar FISH result [HER-2/CEP17 ratio 0.7 (5.7/7.7)] showed 
discrete amplifications of both the centromeric region and the HER-2/neu locus along 
with complex cytogenetic changes that included a relative loss of 17p and a relative gain 
of most of 17q chromosome. 
 
 
 
Figure 9. SNP array karyotype of chromosome 17 demonstrating the copy number 
variability along the length of the chromosome.  
Plot descriptions, A) Raw log2ratio of the tumor/normal for each SNP probe on 
chromosome 17. Copy number of 2 = zero. B) Log2ratio smoothed over 10 SNPs. C) 
Copy number Hidden Markov Model with blue = 1, yellow = 2, pink = 3, pink-red = 4, 
red-pink = 5, and red > 5. 
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4.2.3 Correlation between protein expression and HER-2/neu gene status  
Her-2/neu protein expression results were available for 61 cases. 9 cases 
(14.8%) were negative (scores 0-1+), 30 cases (49.2%) borderline (score 2+) and 22 
cases (36%) positive (score 3+).  
Her-2/neu protein expression positively correlated with both HER-2/neu gene 
copy number and HER-2/CEP17 ratio (p<0.01, rs=0.56 and 0.64, respectively). A trend 
towards positive correlation was found between Her-2/neu protein expression and 
CEP17 copy number, but did not reach the statistical significance (p=0.067). 
Notably, 6/22 cases (27.3%) with Her-2/neu protein scores of 3+ had no HER-
2/neu gene amplification (ratio < 2.2). However, 4 out of these 6 cases harbored more 
than 6 copies of the HER-2/neu gene, fulfilling the absolute copy number criterion for 
HER-2/neu gene amplification (73). In the borderline protein expression category (score 
2+), only 4 of 30 cases had HER-2/neu gene amplification (ratio < 2.2, 13.3%). None of 
the cases with score 0-1+ showed HER-2/neu gene amplification by FISH. 
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5. Discussion 
The diagnosis of apocrine carcinoma of the breast has been controversial 
because of the lack of strict diagnostic criteria. With the increasing use of 
immunohistochemistry, apocrine breast cancer differentiation has shown a consistent 
pattern of steroid receptor expression irrespective of grade (20, 100) and this method 
should be applied for unequivocal definition of this special carcinoma type. With such 
consistency, additional correlations between the histologic phenotype and biologic 
potential should become more meaningful.  
In this study, we applied stringent morphologic and immunohistochemical 
criteria to correctly classify and characterize apocrine carcinoma of the breast. 
Consequently, our results clearly separated breast tumors with apocrine cyto-
morphology into two different groups: the pure apocrine carcinomas with consistent 
lack of ER and overexpression of AR, and morphologically apocrine-like carcinomas 
that did not exhibit the protein expression profile associated with the true apocrine 
phenotype (17, 18, 31, 108). Similarly, Celis et al using another set of morphologic and 
immunohistochemical criteria for classification of apocrine carcinoma defined and 
confirmed the existence of a distinct apocrine carcinoma group with a consistent steroid 
receptor profile (ER-, AR+) (20, 35, 64, 100). Together, these results strongly support 
the recent advances in molecular classification of breast carcinoma which have revealed 
the existence of a specific ‘molecular apocrine’ gene expression profile among ER-
negative breast carcinomas characterized primarily by increased AR signaling, along 
with a common Her-2/neu gene amplification (31, 35, 64, 100). The pure apocrine 
carcinoma subgroup from our study seems to be equivalent to the ‘molecular apocrine’ 
group from Farmers’ study although that cohort was not entirely compatible with pure 
apocrine carcinomas (31). Our findings showing co-expression of AR and Her-2/neu 
proteins in pure apocrine carcinomas also support results of other studies that 
highlighted a functional cross-talk and association between AR and HER-2/neu in a 
subset of breast carcinomas and breast carcinoma cell lines (36-38, 64, 66).  
Pure apocrine carcinomas were further characterized by a complimentary 
expression of Her-2/neu and EGFR proteins. Thus, a majority of HER-2-negative cases 
(i.e. triple-negative apocrine carcinomas) over-expressed EGFR and accordingly could 
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be classified as basal-like breast carcinomas (6, 7, 61, 62, 101). These results are in line 
with a study of Tsutsumi who reported a 100% positivity rate of EGFR protein among 
triple-negative apocrine carcinomas of the breast (27). The author did not however 
explore the status of the EGFR gene. Similar rate of EGFR protein positivity was also 
recently reported by Wen et al (101). On the other hand, HER-2-overexpressing pure 
apocrine carcinomas were mostly negative for EGFR protein expression. However, 
those who were both HER-2/neu and EGFR positive may exhibit Trastuzumab 
resistance as indicated by the recent study (109).  
The apocrine-like carcinomas were much more heterogeneous with various 
combinations of steroid receptor expression including AR. Apocrine-like carcinomas 
are characterized by a common ER expression and HER-2/neu gene amplification but 
significantly less common EGFR over-expression, thus mainly belonging to the luminal 
phenotypes (A and B) according to the molecular classification of breast carcinomas (6, 
7). Notably, of the remaining four ER-negative apocrine-like carcinomas only one case 
had HER-2/neu gene amplification. 
Our results suggest that a strict definition of pure apocrine carcinomas could 
clarify some of the previous contradictions in the classification of apocrine carcinoma 
(variable and heterogeneous gene expression profiles of morphologically defined 
apocrine tumors) that lead some investigators to challenge its existence altogether (42). 
The consistent expression of androgen receptor in pure apocrine carcinomas 
holds promise as a potential therapeutic target (8, 110). Experimental studies showed 
that AR closely interferes with several important oncogenic pathways including 
PI3K/AKT/PTEN and Wnt pathways whose inhibition along with AR blockade results 
in tumor cell growth arrest (36). A recent study of Kasashima et al revealed that a 
substantial proportion of apocrine carcinomas overexpress 5-α reductase that converts 
testosterone into the more potent dihydrotestosterone (29). At clinical level, there are 
several ongoing clinical trials with antiandrogen drugs aimed to treat metastatic and ER-
negative breast cancers (available at: www.clinicaltrials.gov, visited: April 5, 2012 and 
reference 110). These trials should result in definitive guidance in regards to the effects 
of these drugs in treatment of AR-positive breast cancer (110). AR status may also 
affect endocrine response to tamoxifen in patients with ER-positive breast cancers 
(111). 
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Epidermal growth factor receptor (EGFR) is a 170-kDa transmembrane 
glycoprotein encoded by the HER-1 protooncogene, located at 7p11.2-p12 (46, 47, 112). 
High expression of EGFR in a variety of epithelial tumors has led to the development of 
a number of drugs specifically targeting the EGFR that are now in use for treatment of 
advanced colorectal carcinoma, non-small cell lung carcinoma (adenocarcinoma), head 
and neck squamous cell carcinoma, and pancreatic carcinoma (113). EGFR protein 
expression has also been a common finding in breast carcinoma (27), particularly in a 
subgroup of triple-negative, basal-like breast carcinomas (more than 50%) leading some 
investigators to use it as a surrogate marker for a basal-like breast carcinoma (58, 62, 
67). However, EGFR gene alterations (activating mutations and gene amplification) 
tend to be a rare event in breast carcinoma and were found in less than 8% of the cases 
(51, 57, 58, 114). A study of Teng et al recently reported an 11% prevalence of EGFR 
gene mutations in triple-negative breast carcinomas (115).  In the present study, we 
demonstrated EGFR protein expression in 62% of the cases. The expression pattern was 
predominantly strong (scores 2-3+) and diffuse (more than 50% of positive cells) in 
both subgroups and was not accompanied by the EGFR gene amplification, similar to 
the results of a study by Park et al (114).  
Polysomy of chromosome 7 (CEP7 polysomy) which we found associated with 
the pure apocrine carcinoma subgroup is a novel finding, not previously associated with 
apocrine breast cancer (116-119). It also correlated and might be responsible for the 
EGFR protein overexpression in the pure apocrine carcinoma. Of note, Koletsa et al 
recently reported a common CEP7 polysomy in HER-2-positive breast cancers but 
without association with EGFR protein status (67). They also found no EGFR gene 
amplification in any of the cases they studied but confirmed the activation of EGFR 
protein through its phosphorylation (67). CEP7 polysomy have also been observed in 
breast cancers with EGFR protein over-expression including triple-negative basal-like 
breast carcinomas (of no-special-type) as well as in some special types (e.g. metaplastic 
carcinoma of the breast) (56, 57, 119). 
HER-2/neu status is routinely assessed in all patients with a new diagnosis of 
invasive breast carcinoma as it predicts a response to the targeted therapy with 
Trastuzumab (Herceptin ®; Genentech, South San Francisco, CA, USA) (73-77, 83). 
HER-2/neu status has also a prognostic value in breast cancer. Over-expression of Her-
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2/neu protein has been reported in approximately 15% of invasive breast carcinomas 
(NST) and has been associated with a worse clinical outcome (69, 80-82, 120). In most 
cases, Her-2/neu overexpression can be attributed to amplification of the HER-2/neu 
gene located on the long arm of chromosome 17 (17q12) (85). Our study on apocrine 
carcinomas revealed HER-2/neu gene amplification in approximately 52% of the cases, 
similar to the rate of HER-2/neu gene amplification in invasive apocrine carcinomas of 
the breast observed in two previously published small cohorts (44% and 50%, 
references 25 and 121, respectively). The pure apocrine carcinoma subgroup exhibited 
slightly higher rate of HER-2/neu gene amplification in comparison with the apocrine-
like carcinoma subgroup, but the difference was not statistically significant. This is in 
line with previous studies which demonstrated a strong association between HER-2/neu 
status and apocrine differentiation (26, 31, 61, 64, 100, 122). Although we found a high 
degree of concordance between immunohistochemistry and FISH results, four cases 
were negative for HER-2/neu gene amplification despite a high protein expression on 
immunohistochemistry which was previously explained by various preanalytical and 
analytical factors including tissue fixation, a choice of the anti-Her-2/neu antibody, and 
scoring system (122, 123). 
Abnormalities of chromosome 17 are important genetic alterations in breast 
cancer as several important oncogenes, tumor suppressor genes, and DNA repair genes 
are located on it (124). One of the most common genetic events is aneusomy of 
chromosome 17, including polysomy 17 (87, 90). However, the definition of polysomy 
17 is not universally accepted (74). Therefore, we followed the arbitrary cutoff of 3 or 
more copies of CEP17 applied in previous publications (89, 101-102). Our FISH 
analysis revealed CEP17 polysomy in a substantial proportion of apocrine carcinomas 
(33%), either as the sole finding or in combination with HER-2/neu gene amplification. 
CEP17 polysomy without concomitant HER-2/neu gene amplification was seen in eight 
cases of which five cases had Her-2/neu protein overexpression scores 2+ and 3+. 
Several investigators previously considered CEP17 polysomy a potential cause of 
equivocal HER-2/neu results by FISH or immunohistochemistry (90, 101, 125). The 
problem may be related to the methodology and interpretation applied for the HER-
2/neu analysis as the most accurate method of assessing HER-2/neu status is yet to be 
determined (73). In addition, the interpretation guidelines as given by ASCO/CAP may 
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give conflicting results, depending on whether the laboratory uses a single probe kit or a 
double probe kit (73). The most recent ASCO/CAP guidelines for HER-2/neu testing 
define HER-2/neu amplification by FISH as more than six HER-2/neu gene copies per 
nucleus or a ratio HER-2/neu gene signals to chromosome 17 (CEP17) signals of more 
than 2.2 (73). Although this appears rather straightforward, abnormalities of 
chromosome 17 in breast cancer are frequent and may include whole chromosome copy 
number gains (polysomy 17) or losses (monosomy 17), focal copy number gains and 
losses, and other structural rearrangements (88). These abnormalities of chromosome 17 
can lead to discrepant interpretations of FISH data, depending on which criterion is 
used. The potential for such misinterpretations is significant, given that polysomy 17 is 
relatively common in breast carcinomas, although the reported frequency of this finding 
varies in the literature (88-91, 126). The discrepancy may be further complicated by 
different cutoff scoring systems recommended by the FDA (>10% of positive tumor 
cells with score 3+ on IHC or HER-2/CEP17 ratio > 2 on FISH) and ASCO/CAP 
(>30% of positive tumors cells on IHC or HER-2/CEP17 ratio > 2.2 on FISH) (103, 
126). 
In a recently published series by Vanden Bempt et al, more than 40% of breast 
carcinomas were found to harbor increased CEP17 copy number (89). In addition, 
increased CEP17 copy number is frequently found in tumors showing Her-2/neu over-
expression, including those with a borderline (2+) score, as confirmed in our study on 
both apocrine carcinoma and invasive ductal carcinoma of NST (101, 127, 128). Our 
series included unselected (no prior immunohistochemical determination of Her-2/neu 
protein) and selected (equivocal IHC staining results) cases, reflecting CML’s referral 
laboratory’s mixture of cases received from differing institutions.  
Our study on invasive ductal carcinomas (NST) with CEP17 polysomy indicates 
that determination of HER-2/neu amplification status may show discordant results, 
depending on whether CEP17 copy number was taken into account. Indeed, more than 
1/3 of the studied invasive ductal carcinomas (NST) harboring more than 6 copies of the 
HER-2/neu gene did not show HER-2/neu gene amplification (ratio>2.2). Importantly, a 
majority of these cases had a borderline score (2+) on IHC, thus being not amenable for 
the targeted therapy. Similarly, increased CEP17 copy number appears to contribute to 
the discordant results between protein expression and gene amplification (IHC 3+/FISH 
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negative), since 6 out of 22 cases (27%) with a 3+ result on immunohistochemistry did 
not show a HER-2/CEP17 ratio >2.2. Notably, 4 of 6 cases demonstrated greater than 6 
copies of the HER-2 gene. Therefore, these cases did not fit within the HER-2-amplified 
breast carcinoma category (102, 129). Taken together, a subgroup of borderline (2+) 
breast carcinomas represented a majority of the cases with increased CEP17 copy 
number in our study and only 13% of the cases showed HER-2/neu gene amplification. 
This finding is in line with previous studies that confirmed that breast cancers with an 
equivocal IHC score (2+) harbored CEP17 polysomy instead of HER-2/neu gene 
amplification (101, 130, 131). In contrast, Panvichian et al reported no effects of 
isolated CEP17 polysomy on Her-2/neu protein expression (132). 
We point out here that the term “polysomy 17” is commonly used when there is an 
increase in CEP17 signals by FISH. However, FISH analysis is a targeted assay and 
cannot assess the copy number of an entire chromosome. An increased number of 
CEP17 signals may represent a focal gain in the centromeric region of chromosome 17 
rather than a true polysomy 17 (77, 80, 83, 92, 93, 94, 125), and our whole genome 
analysis using SNP arrays in both invasive apocrine carcinoma and invasive ductal 
carcinoma (NST) also supports this observation. Affymetrix 250K Nsp mapping arrays 
contain 4,854 probes on chromosome 17. By generating a SNP array karyotype, one can 
discern between true polysomy 17 and focal gain of CEP17. Our re-analysis of 
published data (GEO dataset record GSE10099) revealed that true polysomy of 
chromosome 17 is a rare event, present in 1% of all analyzed cases (133). Most 
increases in CEP17 copy number by FISH are due to focal gains rather than true 
polysomy 17. Vanden Bempt et al also found neither increased Her-2/neu protein nor 
increased HER-2 mRNA in CEP17 polysomy cases and concluded that the tumors 
displaying unamplified CEP17 polysomy probably represented more Her-2/neu-
negative than HER-2-positive breast carcinomas (89). Some other investigators 
questioned also the interpretation of the CEP17 copy number as a reliable predictor of 
the entire chromosome 17 polysomy (90, 92, 93, 94, 125, 134). Instead of, these 
investigators used the alternative chromosome 17 reference genes (e.g. MED1, 
STARD3, GRB7, TOP2A, RARA) (80, 95). These studies also confirmed that true 
polysomy 17 in breast cancer is uncommon and revealed novel predictors of outcome in 
patients with HER-2-positive breast carcinomas (80). Notably, a study of Lamy et al 
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revealed the key role of HER-2/neu gene in genomic instability along chromosome 17q 
(80). Taken together, we prefer the term CEP17 polysomy and find the term “polysomy 
17” as a potential misnomer. 
Interestingly, CEP17 copy number may have a predictive therapeutic value; 
increased CEP17 copy number along with TOP2A status appear to be a predictive 
marker for anthracycline-based chemotherapy in breast cancer (135-137). However, a 
recent study of Pritchard et al on a larger series of node positive breast carcinomas 
showed a borderline association of CEP17 duplication with clinical responsiveness to 
anthracycline-based chemotherapy (138). 
Similar to gains in CEP17 copy number as seen on FISH testing, deletions of the 
CEP17 copy number do not necessarily correlate with deletion of the entire 
chromosome. In a previous study by Tubbs et al, monoallelic deletion of the HER-2/neu 
gene (HER-2/CEP17≤0.7) was demonstrated in 2% (12/742) of breast carcinomas (139). 
We likewise found deletion of the HER-2/neu gene in a subset of invasive ductal 
carcinomas (NST) with “polysomy” 17 (3/72, 4%) while six cases of apocrine 
carcinomas had fewer HER-2/neu signals per cell than CEP17 signals (ratio: 0.72-0.99). 
Conventional cytogenetics performed on a case of PAC with HER-2/neu gene 
amplification also revealed a loss of chromosome 17 (Figure 4). HER-2/neu gene 
deletion can also be associated with simultaneous loss of the TOP2A gene (140).  
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6. Conclusions 
 Breast carcinomas with apocrine differentiation are heterogeneous in molecular 
terms. The combination of morphologic and immunohistochemical criteria are 
essential for the proper identification of pure apocrine carcinomas. When strictly 
defined, these carcinomas express either Her-2/neu or EGFR in a nearly exclusive 
manner, resulting in their classification as either HER-2-overexpressing or triple-
negative types of breast carcinomas. In contrast, apocrine-like carcinomas 
predominantly belong to the luminal molecular phenotype (both A and B).  
 EGFR and HER-2/neu play important roles in the pathogenesis of apocrine 
carcinomas and these findings may have significant therapeutic implications. HER-
2/neu gene amplification is the primary mechanism of Her-2/neu protein over-
expression. Amplification of the EGFR gene is rarely seen in invasive apocrine 
carcinoma of the breast. Instead of CEP7 polysomy was frequently observed and 
weakly correlated with EGFR protein expression. 
 A consistent AR expression in pure apocrine carcinomas could also have a 
potential therapeutic impact. 
 CEP17 polysomy is a common finding in invasive mammary carcinoma (both 
apocrine and non-apocrine type) and is not necessarily associated with HER-2/neu 
gene amplification. CEP17 polysomy is not a good surrogate for the status of the 
entire chromosome 17 and therefore the term “polysomy 17” should be avoided. 
 CEP17 polysomy may be associated with an equivocal (2+) score on 
immunohistochemistry. It can lead to discrepant interpretations depending on 
which criterion for the interpretation was used: HER-2/CEP17 ratio versus absolute 
HER-2/neu gene copy. However, positive gene dosage (>6 HER-2/neu genes or 
HER-2/CEP17 ratio>2.2), regardless of the evaluation method used, is positively 
correlated with Her-2/neu protein expression. As a result of our findings, we 
propose that the average number of HER-2/neu genes per nucleus be reported 
alongside the average HER-2/CEP17 ratio and Her-2/neu protein status, in order to 
accurately identify all patients eligible for trastuzumab treatment. 
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7. Summary 
The study was undertaken to investigate EGFR and HER-2/neu expression in a 
cohort of apocrine carcinomas of the breast with emphasis on the classification of the 
breast carcinomas with apocrine morphology. In total, 55 breast carcinomas 
morphologically diagnosed as apocrine were evaluated for steroid receptor expression 
profile characteristic of normal apocrine epithelium (ER-/PR-/AR+), and for the 
expression of EGFR and Her-2/neu proteins, and the copy number ratios of the genes 
EGFR/CEP7 and HER-2/CEP17. Another cohort composed of 72 invasive ductal 
carcinomas of no-special-type was used to further determine the impact of CEP17 
polysomy on the interpretation of HER-2/neu testing. 
Our study confirms that apocrine carcinomas of the breast are molecularly 
diverse group of carcinomas. Strictly defined, pure apocrine carcinomas (ER-, PR-, 
AR+) (38 cases, 69%) are either HER-2 overexpressing breast carcinomas (52%) or 
triple-negative breast carcinomas (48%). Apocrine-like carcinomas (ER+/-, PR+/-, 
AR+/-) (17 cases, 31%) belong predominantly to the luminal phenotype (76%).  
Pure apocrine carcinomas show consistent over-expression of either EGFR or 
Her-2/neu. EGFR gene amplification was observed in two pure apocrine carcinomas 
and one apocrine-like carcinoma. CEP7 polysomy (defined as three or more CEP7 
signals) was seen in 61% pure apocrine carcinomas and 27% of apocrine-like 
carcinomas and showed a weak positive correlation with EGFR protein expression.  
HER-2/neu gene amplification is the primary mechanism of Her-2/neu activation 
and is found in 52% of all apocrine carcinomas. CEP17 polysomy (defined as three or 
more CEP17 signals) was observed in 10 pure apocrine carcinomas (32%) and 8 
apocrine-like carcinomas (50%).  
CEP17 polysomy may be seen without HER-2/neu gene amplification. Further 
exploration on a cohort of invasive ductal carcinomas of no-special-type confirmed that 
increased CEP17 signals may lead to discordant interpretation of HER-2/neu gene 
amplification in a significant proportion of the cases, depending on which criterion 
(ratio versus absolute number) is used for interpretation. However, increased gene 
dosage (>6 HER-2/neu genes or HER-2/CEP17 ratio>2.2), regardless of the evaluation 
method, is positively correlated with Her-2/neu protein expression. 
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8. Sažetak 
Cilj istraživanja je bio ispitati ekspresiju EGFR i Her-2/neu proteina u skupini 
apokrinih karcinoma dojke s posebnim osvrtom na klasifikaciju karcinoma dojke s 
apokrinom morfologijom. Ukupno 55 karcinoma dojke s apokrinom morfologijom 
testirano je na karakteristični profil steroidnih receptora koji se susreće kod normalnog 
apokrinog epitela (ER-/PR-/AR+), ekspresiju Her-2/neu i EGFR proteina, te broj kopija 
i odnos HER-2/CEP17 i EGFR/CEP7. Dodatna skupina sastavljena od 72 karcinoma 
dojke (opći tip) poslužila je za daljnje ispitivanje utjecaja polisomije CEP17 na status i 
interpretaciju HER-2/neu gena. 
Rezultati istraživanja pokazuju da su apokrini karcinomi dojke molekularno 
heterogena skupina tumora. Striktno definirani, tzv. čisti apokrini karcinomi (ER-/PR-
/AR+) (38 slučajeva, 69%) su ili HER-2 pozitivni (52%) ili “trostruko-negativni” 
karcinomi (48%). “Apocrine-like” karcinomi dojke (ER+/-, PR+/-, AR+/-) (17 
slučajeva, 31%) pripadaju pretežno luminalnom fenotipu (76%).  
Čisti apokrini karcinomi pokazuju konzistentnu ekspresiju ili EGFR ili HER-
2/neu. Amplifikacija EGFR gena je bila utvrđena kod 2 čista apokrina i jednog 
„apocrine-like“ karcinoma dojke. Polisomija CEP7 (definirana kao tri i više CEP7 
signala) je bila prisutna kod 61% čistih apokrinih i 27% „apocrine-like“ karcinoma 
dojke. Polisomija CEP7 je pokazivala statistički slabu pozitivnu korelaciju s 
ekspresijom EGFR proteina. 
Amplifikacija HER-2/neu gena je osnovni mehanizam aktivacije Her-2/neu 
proteina i pronađena je kod 52% svih apokrinih carcinoma. Polisomija CEP17 
(definirana kao tri ili više CEP17 kopija) je bila prisutna kod 10 čistih apokrinih 
karcinoma (32%) i 8 „apocrine-like“ karcinoma dojke (50%).  
Polisomija CEP17 se može javiti i bez amplifikacije HER-2/neu gena. Daljnja 
analiza utjecaja polisomije CEP17 na kohorti invazivnih karcinoma dojke (opći tip) 
potvrdila je da povećani broj CEP17 signala može utjecati na proturječnu interpretaciju 
amplifikacije HER-2/neu gena kod signifikantnog broja karcinoma dojke, ovisno koji 
kriterij za interpretaciju se primjenjuje (odnos HER-2/CEP17 naspram apsolutnog broja 
kopija HER-2/neu gena). Ipak, povećana količina gena (>6  kopija HER-2/neu gena ili 
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odnos HER-2/CEP17>2.2), bez obzira na način interpretiranja je pozitivno korelirala s 
ekspresijom Her-2/neu proteina. 
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Assessment of HER2 Gene Status in
Breast Carcinomas With Polysomy of
Chromosome 17
Semir Vranic, MD1,2; Bryan Teruya, MD1; Susan Repertinger, MD1; Pamela Ulmer, MD1;
Jill Hagenkord, MD1; and Zoran Gatalica, MD, DSc1
BACKGROUND: The current study was performed to determine the impact of polysomy 17 on the interpretation of
HER2 testing of invasive breast carcinomas using fluorescent in situ hybridization methods. Current American Society
of Clinical Oncology/College of American Pathologists guidelines define HER2-positive tumors as those with >6
HER2 genes per nucleus or those with HER2/CEP17 (chromosome 17) ratio >2.2. These guidelines are potentially con-
tradictory in tumors with polysomy of chromosome 17. METHODS: Seventy-two breast carcinoma cases with reported
polysomy of chromosome 17 (3 CEP17 signals on average) by fluorescent in situ hybridization were identified, and
the corresponding HER2 immunohistochemistry was obtained. The HER2 status of the archived samples was
reviewed, and the tumors were recategorized according to the 2007 American Society of Clinical Oncology/College
of American Pathologists guidelines. RESULTS: The average CEP17 copy number for the group was 4.5 (range, 3.0-
10.4). Thirty-three (45.8%) cases had >6 copies of HER2 per nucleus. Twenty-one cases (29.2%) qualified as HER2
gene amplified using the HER2/CEP17 ratio (>2.2) guideline. All these cases had >6 HER2 signals, which represented
63.6% of all cases with >6 HER2 signals. HER2 protein expression showed significant positive correlations with both
HER2 gene copy number and HER2/CEP17 ratio (P < .01, rs ¼ 0.56 and 0.64, respectively). CONCLUSIONS: Increased
CEP17 signals detected in invasive breast carcinomas may lead to discordant interpretation of gene amplification in a
significant proportion of the cases, depending on which criterion (ratio vs absolute number) is used for interpreta-
tion. However, increased gene dosage (>6 HER2 genes or HER2/CEP17 ratio >2.2), regardless of the evaluation
method, is positively correlated with HER2 protein expression. Cancer 2011;117:48–53. VC 2010 American Cancer
Society.
KEYWORDS: breast cancer, HER2, fluorescent in situ hybridization, amplification, CEP17 polysomy.
HER2 status in breast carcinomas has become a standard prognostic marker and is an essential test for the selection of
breast cancer patients eligible for the targeted therapy (eg, trastuzumab and lapatinib).1,2 Trastuzumab, a humanized
monoclonal antibody that targets the HER2 protein, is routinely used in the treatment of patients with breast carcinoma
overexpressing this protein. Approximately 20% of breast cancers show HER2 overexpression and are characterized by
decreased relapse-free time and overall survival.3 Therefore, trastuzumab therapy is widely used as a first-line cancer treat-
ment in breast cancer patients whose primary or metastatic tumors overexpress the HER2 protein.4 Trastuzumab
improves response rates and survival, and decreases time to progression when used alone or when added to chemotherapy
in metastatic breast cancer.5 Given the significant clinical benefits of trastuzumab in patients with HER2-positive breast
cancer, it is of paramount importance to accurately identify all patients eligible for this therapy.
The primary mechanism of HER2 overexpression is amplification of the HER2 gene on chromosome 17,6 which is
typically detected by fluorescence in situ hybridization (FISH), although other in situ hybridization methods are now
increasingly used (chromogenic and silver in situ hybridization) as well as array comparative genomic hybridization. For
FISH analysis, 3 kits approved by the US Food and Drug Administration are available: 1) PathVysion (Abbott
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Laboratories, Abbott Park, Ill), 2) INFORM (Ventana
Medical Systems, Tucson, Ariz), or 3) PHarmDx
(DAKO, Glostrup, Denmark). The INFORM kit evalu-
ates only the HER2 gene copy number, and results are
based on the absolute HER2 signal count. The Path-
Vysion and PHarmDx kits use 2 probes, a HER2 probe
and a CEP17 (chromosome 17 centromere enumeration
probe) hybridization control probe, and results are based
on theHER2/CEP17 ratio.
Current American Society of Clinical Oncology/
College of American Pathologists guidelines now define
HER2-positive tumors as those with an average HER2
gene copy number of>6 gene copies per nucleus (for sin-
gle probe assays) or as a HER2/CEP17 ratio of >2.2 (for
double probe assays).3 Typically, similar conclusions are
obtained with either the absolute HER2 signal count or
the HER2/CEP17 ratio,7 but discrepancies can occur in
cancers with increased CEP17 copy number (>3 copies
per tumor cell). For example, tumors with increased
CEP17 copy number and slightly increased HER2 copy
number may be considered amplified by single probe
assays but unamplified by double probe assays. It is esti-
mated that this occurs in 2% to 9% of breast cancers.8,9
However, the reported frequency of CEP17 copy number
alteration in breast cancer varies, depending on the study
population, selection criteria, and the definition of chro-
mosome 17 polysomy (CEP17).10-13 In the literature, it is
commonly assumed that an increase in CEP17 copy num-
ber is because of polysomy 17, and these terms have been
used interchangeably. However, it is important to recog-
nize that an increase in CEP17 signals does not necessarily
represent a true polysomy (ie, gain of the entire chromo-
some), but rather may represent a focal pericentromeric
gain or a partial polysomy.12,14
We have investigated the effect of increased CEP17
signal number on the interpretation of FISH results in
breast cancers diagnosed at our institution. We confirm
that increased CEP17 signals may lead to discordant
interpretations between theHER2/CEP17 ratio and abso-
lute HER2 gene copy number in a significant proportion
of cases.
MATERIALS AND METHODS
Patients
Retrospective review of pathology reports from Creighton
Medical Laboratories (Creighton University, Omaha,
Neb) identified 72 patients whose breast cancers had 3
CEP17 signals per nucleus on average by FISH. The
cohort represented approximately 12% of all tested cases
in the period 2003 to 2007. The study was approved by
the Creighton University Institutional Review Board.
Fluorescent In Situ Hybridization
Formalin-fixed paraffin-embedded tissue sections were
used in all cases.
Two-color FISH was performed on 3.5 lm-thick
sections from the paraffin blocks. Before hybridization,
sections were deparaffinized, dehydrated in 100% etha-
nol, and air dried. Commercially available Locus Specific
IdentifierHER2 probe (190 Kb SpectrumOrange directly
labeled fluorescent DNA probe) and a CEP17 probe (5.4
Kb Spectrum Green directly labeled fluorescent DNA)
were used according to the manufacturer’s recommenda-
tions (PathVysion, Abbott Molecular, Des Plaines, Ill).
Thirty nuclei were scored per sample, and the number of
HER2 (orange) and CEP17 (green) signals were recorded.
A ratio of HER2 to CEP17 >2.2 was defined as gene
amplification; polysomy 17 was defined as3 CEP17 sig-
nals per nucleus (average for 30 cells).
Immunohistochemistry
Immunohistochemical assay for HER-2/neu (IgG1,
Clone CB11, Ventana Medical Systems) expression was
performed using a commercially available detection kit
and automated staining procedures (Benchmark, Ventana
Medical Systems).
Automated Cell Imaging System (ACIS, Chroma-
Vision Medical Systems, San Juan Capistrano, Calif) was
used for measuring the percentage of cells with membra-
nous staining of HER2 protein. This system combines
color-based imaging technology with automated micros-
copy to provide quantitative information on the intensity
and the percentage of cells with positive staining; patholo-
gists reviewed the images on screen and selected tumor-
rich areas for analysis. The Automated Cell Imaging
System scoring system for HER2 protein was as follows:
score <1.0 (negative, equivalent to 1þ), score 1.0 to 2.4
(borderline, 2þ), and score2.4 (positive, 3þ).
Single Nucleotide Polymorphism Array
Single nucleotide polymorphism (SNP) array karyotyping
was performed on 2 selected cases with borderline score
(2þ) of HER-2/neu protein on immunohistochemistry
(IHC) and polysomy 17 (3 signals of CEP17 per
nucleus) on FISH. After tumor enrichment via manual
microdissection, DNA was obtained from 10 lm paraffin
sections as described previously,15 and 250K Nsp Assay
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Kits (Affymetrix, Santa Clara, Calif) were used according
to the manufacturer’s protocol, except for increased start-
ing genomic DNA. One microgram of genomic DNA
was digested withNsp restriction enzyme, ligated to adap-
tors, and amplified by polymerase chain reaction (PCR)
using a universal primer. After purification of PCR prod-
ucts with SNP Clean magnetic beads (Agencourt Bio-
sciences, Beverly, Mass), amplicons were quantified,
fragmented, labeled, and hybridized to 250K Nsp arrays.
After washing and staining, the arrays were scanned to
generate CEL files for downstream analysis.
Data acquired from the Affymetrix Gene-Chip
Operating System v4.0 were analyzed using Affymetrix
Gene-Chip Genotyping Analysis Software v4.1. Copy
number analysis was performed with Copy Number Ana-
lyzer for Affymetrix GeneChip arrays v3.0, as previously
described.16
Statistical Analysis
A nonparametric chi-square test was used for testing asso-
ciations between variables. For correlation purposes, the
nonparametric Spearman correlation rank was used. All
statistical tests were 2-sided, and P values <.05 were con-
sidered statistically significant. Statistical analysis was per-
formed using the Statistical Package for Social Sciences
software (v17.0; SPPS Inc, Chicago, Ill).
RESULTS
Clinicopathologic Characteristics of the
Cohort
All but 2 patients were women. The patient’s age ranged
between 34 and 99 years (mean, 58.3 years). The study
included 68 primary and 4 metastatic breast carcinomas.
The majority of the cases were invasive ductal carcinomas
of no special type (65 cases, 90.3%). The remaining cases
included 3 mucinous carcinomas (4.2%), 1 case of inva-
sive lobular carcinoma (1.4%), 1 case of mammary Paget
disease in association with invasive ductal carcinoma
(1.4%), and 2 cases of ductal carcinoma in situ (2.8%).
FISH Results and Interpretation
The HER gene and CEP17 copy number, HER2/CEP17
ratio, and HER2 protein expression results are summar-
ized in Table 1 and Figure 1 (Euler diagram). Average
CEP17 copy number for the cohort was 4.5 and ranged
from 3.0 to 10.4 (Fig. 2). HER2 gene amplification as
defined as the ratio ofHER2/CEP17>2.2, was identified
in 21 cases (29.2%). All these cases had >6 HER2 signals
per nucleus. More than 6 HER2 copies per nucleus were
observed in an additional 12 cases without an increased
HER2/CEP17 ratio, for a total of 33 cases (45.8% of all
cases); using the criterion of>6HER2 signals per nucleus
as positive for amplification, these 33 cases would be
categorized asHER2 amplified. These findings, therefore,
demonstrate that discrepant interpretation of gene ampli-
fication status was detected in 12 (36.4%) cases when the
number of CEP17 copies was taken into account. Of these
12 cases, HER-2/neu protein IHC was available for 10
cases: 3 cases had HER2 overexpression (score 3þ), and
6 cases had borderline score (2þ), whereas 1 case was
negative (score 1þ).
Interestingly, HER2/CEP17 ratios <1.0 were
observed in 9 (12.5%) cases, of which 3 (4%) cases had a
HER2/CEP17 ratio 0.7. One of these cases had a ratio
Table 1. Results of the Immunohistochemistry and
Fluorescent In Situ Hybridization in a Cohort of 72
Cases with CEP17 Polysomy
HER2 Gene Copy
No.
HER2/CEP17
Ratio
>6 copies, 33 (45.8%) >2.2, 21 (29.2%)
6 copies, 39 (54.2%) <2.2, 51 (70.8%)
CEP17 Copy No. HER-2/neu Protein Expression
>6 copies, 9 (12.5%) 2.4 (score 3þ), 22 (36.1%)
6 copies, 63 (87.5%) <2.4 (score 0 to 2þ), 39 (63.9%)
HER2 indicates human epidermal growth factor receptor 2.
Figure 1. A Euler diagram showing the subdistribution of
cases of breast carcinomas with CEP17 polysomy is
presented.
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of<0.5 (1.71HER2 signals and 4.06 CEP17 signals, ratio
¼ 0.42), indicating that amplification of the centromeric
region may not be accompanied by amplification of the
HER2 gene region in some cases.
SNP Array Karyotyping and Interpretation
Cytogenomic arrays provide high-resolution, genome-
wide copy number information. Affymetrix 250K Nsp
mapping arrays contain 250,000 probes genome-wide,
including 4854 probes on chromosome 17, and were used
in 2 cases in our series to further investigate the relation-
ship between CEP17,HER2 gene, and other loci on chro-
mosome 17. SNP array analysis of the first case, with a
FISHHER2/CEP17 ratio of 0.7 (2.3 of 3.3), revealed that
copy number variability occurring along chromosome 17
may be undetected when using 1 or 2 FISH probes to
determine chromosome 17 copy number. In this case, the
copy number at the CEP17 locus is 3, whereas that at the
HER2 locus is 2, generating a ratio of 0.67 (Fig. 3).
Another case with similar FISH result (HER2/CEP17 ra-
tio 0.7 [5.7 of 7.7]) showed discrete amplifications of
both the centromeric region and the HER2 locus along
with complex cytogenetic changes that included a relative
loss of 17p and a relative gain of most of the 17q
chromosome.
Correlation Between Protein Expression
and HER2 Gene Status
HER2 protein expression results were available for 61
cases. Nine (14.8%) cases were negative (scores 0-1þ), 30
(49.2%) cases were borderline (score 2þ), and 22 (36%)
cases were positive (score 3þ).
HER2 protein expression positively correlated with
bothHER2 gene copy number andHER2/CEP17 ratio (P
< .01, rs ¼ 0.56 and 0.64, respectively). A trend toward
positive correlation was found between HER2 protein
expression and CEP17 copy number, but did not reach
statistical significance (P¼ .067).
Notably, 6 (27.3%) of 22 cases with HER2 protein
scores of 3þ had no HER2 gene amplification (ratio,
<2.2). However, 4 of these 6 cases harbored>6 copies of
the HER2 gene, fulfilling the absolute copy number crite-
rion forHER2 gene amplification.3 In the borderline pro-
tein expression category (score 2þ), only 4 of 30 cases had
HER2 gene amplification (ratio, <2.2; 13.3%). None of
the cases with score 0 to 1þ showed HER2 gene amplifi-
cation by FISH.
DISCUSSION
HER2 status is routinely assessed in all patients with a new
diagnosis of invasive breast carcinoma. However, the
most accurate method of assessing HER2 status is yet to
be determined, and interpretation guidelines3 as given by
American Society of Clinical Oncology/College of Ameri-
can Pathologists may give conflicting results, depending
Figure 2. A dual-color fluorescent in situ hybridization assay
demonstrating multiple copies of the CEP17 (green) and
HER2 (red) genes is shown.
Figure 3. A single nucleotide polymorphism (SNP) array
karyotype of chromosome 17 demonstrating the copy num-
ber variability along the length of the chromosome is shown.
(A) Raw log2 ratio of the tumor/normal for each SNP probe
on chromosome 17 is shown. A copy number of 2 indicates 0.
(B) Log2 ratio smoothed over 10 SNPs is shown. (C) A copy
number hidden Markov model is shown, in which blue indi-
cates 1; yellow, 2; pink, 3; pink-red, 4; red-pink, 5; and red >5.
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on whether the laboratory uses a single probe kit or a
double probe kit. The most recent American Society of
Clinical Oncology/College of American Pathologists
guidelines for HER2 testing define HER2 amplification
by FISH as >6 HER2 gene copies per nucleus or a ratio
(HER2 gene signals to chromosome 17 signals) of >2.2.3
Although this appears rather straightforward, abnormal-
ities of chromosome 17 in breast cancer are frequent and
may include whole chromosome copy number gains (pol-
ysomy 17) or losses (monosomy 17), focal copy number
gains and losses, and other structural rearrangements.10
These abnormalities of chromosome 17 can lead to dis-
crepant interpretations of FISH data, depending on which
criterion is used.
The potential for such misinterpretations is signifi-
cant, given that polysomy 17 is relatively common in
breast carcinomas, although the reported frequency of this
finding varies in the literature.10-13 In a recently published
series by Vanden Bempt et al,>40% of breast carcinomas
were found to harbor increased CEP17 copy number.11
Our recent study on apocrine carcinoma of the breast also
revealed increased CEP17 copy number in 33% of the
apocrine carcinomas of the breast.17 The present study
also revealed a smaller overall proportion (12% of all
tested cases) of increased CEP17 copy number cases, com-
posed predominantly of invasive breast carcinomas of no
special type. In addition, increased CEP17 copy number
is frequently found in tumors showing HER2 overexpres-
sion, including those with a borderline (2þ) score, as con-
firmed in our study.18-20 Our series included unselected
(no prior IHC determination of HER-2/neu protein) and
selected (equivocal IHC staining results) cases, reflecting
our referral laboratory’s mixture of cases received from
different institutions.
HER2 status determination by FISH depends on the
criteria used.21 Our study indicates that determination of
HER2 amplification status may show discordant results,
depending on whether CEP17 copy number was taken
into account. Indeed, more than one-third of the studied
cases harboring>6 copies of theHER2 gene did not show
HER2 gene amplification (ratio, >2.2). Importantly, a
majority of these cases had a borderline score (2þ) on
IHC, and therefore were not amenable for the targeted
therapy. Similarly, increased CEP17 copy number
appears to contribute to the discordant results between
protein expression and gene amplification (IHC 3þ/
FISH negative), because 6 (27%) of 22 cases with a 3þ
result on IHC did not show a HER2/CEP17 ratio >2.2.
Notably, 4 of 6 cases demonstrated >6 copies of the
HER2 gene. Therefore, these cases did not fit within the
HER2-amplified breast carcinoma category.21,22 Taken
together, a subgroup of borderline (2þ) breast carcinomas
represented a majority of the cases with increased CEP17
copy number in our study, and only 13% of the cases
showed HER2 gene amplification. This finding is in line
with previous studies that confirmed that breast cancers
with an equivocal IHC score (2þ) harbored CEP17 pol-
ysomy instead ofHER2 gene amplification.18,23,24
It is common in the literature to use the term poly-
somy 17 when there is an increase in CEP17 signal by
FISH. However, FISH analysis is a targeted assay and can-
not assess the copy number of an entire chromosome. An
increased number of CEP17 signals may represent a focal
gain in the centromeric region of chromosome 17 rather
than a true polysomy 17. Affymetrix 250K Nsp mapping
arrays contain 4854 probes on chromosome 17. By gener-
ating a SNP array karyotype, one can discern between true
polysomy 17 and focal gain of CEP17. Our reanalysis of
published data (GEO dataset record GSE10099) revealed
that true polysomy of chromosome 17 is a rare event,
present in 1% of all analyzed cases.25 Most increases in
CEP17 copy number by FISH are because of focal gains
rather than true polysomy 17. This finding has been
reported by others.14,26
Interestingly, CEP17 copy number may have a pre-
dictive therapeutic value; increased CEP17 copy number
appears to be a predictive marker for anthracycline-based
chemotherapy in breast cancer.27,28
Similar to gains in CEP17 copy number as seen on
FISH testing, deletions of the CEP17 copy number do
not necessarily correlate with deletion of the entire chro-
mosome. In a previous study by Tubbs et al,HER2mono-
allelic deletion (HER2/CEP17 0.7) was demonstrated
in 2% (12 of 742) of breast carcinomas.29 We likewise
found deletion of the HER2 gene in a subset of cases with
polysomy 17 (3 of 72, 4%). This finding is also supported
by the SNP array karyotype of the 2 cases included in the
present study.
In summary, we found that increased CEP17 copy
number (3 copies of CEP17) is seen in 12% of breast
tumors undergoing routine assessment of HER2 gene sta-
tus. Half of these cases exhibited an equivocal (2þ) score
on IHC. Furthermore, a significant proportion of cases
showing increased CEP17 copy number led to discrepant
interpretations based on which criterion was used (HER2/
CEP17 ratio vs absolute HER2 gene copy). However,
positive gene dosage (>6 HER2 genes or HER2/CEP17
ratio >2.2), regardless of the evaluation method used, is
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positively correlated with HER2 protein expression. As a
result of our findings, we propose that the average number
ofHER2 genes per nucleus be reported alongside the aver-
age HER2/CEP17 ratio, to accurately identify all patients
eligible for trastuzumab treatment.
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EGFR and HER-2/neu expression in invasive
apocrine carcinoma of the breast
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Lisa MJ Lee1, Patrick Adegboyega5, Jill Hagenkord1 and Zoran Gatalica1
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This study was undertaken to investigate epidermal growth factor receptor (EGFR) and human epidermal
growth factor receptor 2 (HER-2)/neu expression in a cohort of apocrine carcinomas of the breast with emphasis
on the classification of the breast tumors with apocrine morphology. In total, 55 breast carcinomas
morphologically diagnosed as apocrine were evaluated for the steroid receptor expression profile characteristic
of normal apocrine epithelium (androgen receptor positive/estrogen receptor (ER) negative/progesterone
receptor (PR) negative), and for the expression of EGFR and Her-2/neu proteins, and the copy number ratios of
the genes EGFR/CEP7 and HER-2/CEP17. On the basis of the results of steroid receptors expression, 38 (69%)
cases were classified as pure apocrine carcinoma (androgen receptor positive/ER negative/PR negative),
whereas 17 (31%) were re-classified as apocrine-like carcinomas because they did not have the characteristic
steroid receptor expression profile. Her-2/neu overexpression was observed in 54% of the cases (57% pure
apocrine carcinomas vs 47% apocrine-like carcinomas). HER-2/neu gene amplification was demonstrated in
52% of all cases (54% pure apocrine carcinomas vs 46% apocrine-like carcinomas). EGFR protein (scores 1 to
3þ ) was detected in 62% of all cases and was expressed in a higher proportion of pure apocrine carcinomas
than in the apocrine-like carcinomas group (76 vs 29%, P¼ 0.006). In the pure apocrine carcinoma group, Her-2/
neu and EGFR protein expression were inversely correlated (P¼ 0.006, r¼0.499). EGFR gene amplification
was observed in two pure apocrine carcinomas and one apocrine-like carcinoma. Polysomy 7 was commonly
present in pure apocrine carcinomas (61 vs 27% of apocrine-like carcinomas; P¼ 0.083) and showed a weak
positive correlation with EGFR protein expression (P¼ 0.025, r¼ 0.326). Our study showed that apocrine breast
carcinomas are molecularly diverse group of carcinomas. Strictly defined pure apocrine carcinomas are either
HER-2-overexpressing breast carcinomas or triple-negative breast carcinomas, whereas apocrine-like
carcinomas predominantly belong to the luminal phenotype. Pure apocrine carcinomas show consistent
overexpression of either EGFR or HER-2/neu, which could have significant therapeutic implications.
Modern Pathology (2010) 23, 644–653; doi:10.1038/modpathol.2010.50; published online 5 March 2010
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Apocrine carcinomas of the breast, defined as breast
tumors composed of epithelium with apocrine
differentiation in 490% of the tumor cell popula-
tion, represent a rare subtype, constituting o5% of
all breast cancers.1–3 Apocrine differentiation is
defined by the presence of large cells with promi-
nent eosinophilic, flocculent cytoplasm, with shar-
ply defined cell borders, and with large nuclei
containing prominent macronucleoli. Importantly, a
characteristic steroid receptor expression profile
further defines these tumors as consistently estrogen
receptor (ER) negative, progesterone receptor (PR)
negative and androgen receptor (AR) positive.4–8
Received 29 July 2009; revised and accepted 25 January 2010;
published online 5 March 2010
Correspondence: Dr Z Gatalica, MD, DSc, Department of Pathol-
ogy, Creighton University Medical Center, 601 N 30th Street,
Omaha, NE 68131, USA.
E-mail: zorangatalica@creighton.edu
Modern Pathology (2010) 23, 644–653
644 & 2010 USCAP, Inc. All rights reserved 0893-3952/10 $32.00
www.modernpathology.org
Although AR expression has been variably observed
in up to 60–70% breast carcinomas,9,10 consistent
AR expression tends to be a feature of apocrine
breast lesions including invasive apocrine carcino-
mas.4,5,8,11,12 Moreover, recently published gene
expression microarray studies defined a character-
istic ‘molecular apocrine’ gene expression profile
found in apocrine carcinomas. These studies
showed apocrine tumors to be different from
common luminal and basal cell breast carcinoma
subtypes.13–16 This molecular apocrine group was
characterized by increased AR signaling along with
increased human epidermal growth factor receptor
2 (HER-2)/neu gene signaling.13,16 A study using
an apocrine cell line model also demonstrated the
existence of a functionally significant cross-talk
between AR and HER-2/neu pathways through
ERK1/2 in ER-negative breast carcinomas.17 This
cross-talk affects cell proliferation and apoptosis
and could have a significant therapeutic impact.17
Although apocrine carcinoma exhibits distinctive
histopatological and molecular features, the lack
of standardized diagnostic criteria has produced
controversial and heterogeneous results in the
scientific literature in terms of its immunohisto-
chemical profile and molecular classification.2,18–20
The erbB (HER) family is comprised of four
homologous transmembrane receptors involved in
growth factor cellular signaling.21 Epidermal growth
factor receptor (EGFR) (or HER-1) and HER-2/neu
genes are of particular importance in breast cancer
pathogenesis as their activation and coexpression are
associated with an aggressive clinical course and a
poor outcome.22 Both proteins can be targeted by
specific therapeutic modalities. However, these tyr-
osine kinase receptors have not been systematically
studied in invasive apocrine carcinomas of the breast.
We studied EGFR and HER-2/neu in apocrine
breast carcinomas meeting strict morphological and
immunophenotypic criteria with regard to both
protein expression and gene copy number. We
identified significant differences between pure
apocrine carcinoma (apocrine morphology and a
characteristic ARþ /ER/PR steroid receptor pro-
file) and apocrine-like breast carcinomas (apocrine
morphology without characteristic apocrine steroid
receptor profile), which could have important
diagnostic and therapeutic implications.
Materials and methods
Specimens
The formalin-fixed paraffin-embedded tumor sam-
ples were obtained from 55 female patients with
invasive apocrine carcinomas (52 surgical and 3
core biopsy specimens). Mean age of patients was 62
years (range: 32–92 years). The cases were retrieved
from the files of Creighton University Medical
Center (Omaha, NE, USA), Kansas University
Medical Center (Kansas City, KS, USA), Thomas
Jefferson University Hospital (Philadelphia, PA,
USA), The University of Texas Medical Branch
(Galveston, TX, USA) and Clinical Center of the
University of Sarajevo (Bosnia and Herzegovina).
Routinely stained hematoxylin and eosin tumor
sections were re-examined (ZG and SV) and the
diagnoses were confirmed. Institutional review board
of the Creighton University approved the study.
Immunohistochemistry
Immunohistochemical assays for ER-alpha (ER-a;
clone 6F11, Ventana Medical Systems, Tucson, AZ,
USA), PR (clone 16, Ventana Medical Systems), AR
(Clone AR441, DakoCytomation, Carpinteria, CA,
USA), EGFR (DAKO EGFR PharmDX diagnostic kit;
DakoCytomation) and Her-2/neu (Clone CB11, Ven-
tana Medical Systems) expression were performed
on the formalin-fixed paraffin-embedded sections
using the commercially available detection kits and
automated staining procedures.
The tumor was regarded as positive for ER and PR if
45% of the cells showed nuclear staining, whereas a
10% cutoff was applied for AR staining.8,23
Her-2/neu protein expression results were scored
according to the American Society of Clinical
Oncology/College of American Pathologists Guide-
line Recommendations.24 Briefly, cases showing no
membrane immunostaining or membrane immunos-
taining ino10% tumor cells were scored 0þ ; cases
with weak and incomplete membrane staining in
410% of tumor cells were scored 1þ ; cases with
complete membrane staining that was either non-
uniform or weak in intensity but with obvious
circumferential distribution in 410% of cells were
scored 2þ ; and cases with strong membrane stain-
ing in 430% tumor cells were scored 3þ .24
EGFR scoring was carried out according to the
manufacturer’s (Dako) recommendation: only mem-
branous staining is considered as a specific positive
result; weak (1þ ) intensity is defined as faint and
incomplete membrane positivity; moderate (2þ )
intensity and strong (3þ ) staining are both varying
degrees of circumferential staining of membranes.
The tumor was considered positive if a proportion of
stained cells exceeded 1% at any intensity.
Automated Cell Imaging System (ChromaVision
Medical Systems, San Juan Capistrano, CA, USA)
was used for measuring the percentage of cells with the
nuclear staining for ER, PR and AR, and the extent and
intensity of membranous staining of EGFR and Her-2/
neu. Pathologists reviewed the images and selected
tumor-rich areas of the sections for the analysis.
FISH Analysis
Fluorescent in situ hybridization (FISH) was per-
formed to evaluate copy number at EGFR and HER-
2/neu loci. Chromosome enumeration probes CEP7
and CEP17 were used as positive controls and
EGFR and HER-2/neu in apocrine carcinoma
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indicators of chromosome ploidy (Abbott Molecular,
Des Plaines, IL, USA). Probe signals were enumer-
ated in predominant tumor cell populations. At least
30 nuclei were scored per sample. A ratio of HER-2/
CEP17 42.2 was defined as gene amplification; a
ratio 1.8–2.1 was interpreted as borderline, and a
ratio o1.8 was defined as negative. The same
criteria were used for interpretation of EGFR/CEP7
ratios. Equivocal FISH results (ratio of 1.8–2.2) were
considered as negative for HER-2/neu and EGFR
gene amplification, respectively.24 Polysomy 7 and
17 were defined as three or more CEP signals per
cell.21,25,26 Stromal cells and normal breast epithelial
cells served as an internal control.
SNP Array Karyotyping
SNP array karyotyping was performed on selected
cases. Following tumor enrichment through manual
microdissection, DNA was obtained from 10-mm
paraffin sections according to a previously de-
scribed protocol for de-paraffinization and DNA
extraction.27 Samples were processed with the 250K
Nsp Assay Kits (Affymetrix, Santa Clara, CA, USA).
Briefly, 1mg of gDNA was digested with Nsp
restriction enzyme, ligated to the adaptors and
amplified by PCR using a universal primer. After
purification of PCR products with SNP Clean
magnetic beads (Agencourt Biosciences, Beverly
MA, USA), amplicons were quantified, fragmented,
labeled and hybridized to 250K Nsp arrays. After
washing and staining, the arrays were scanned to
generate CEL files for downstream analysis.
Data acquired from the Affymetrix GeneChip
Operating System v4.0 (GCOS) was analyzed using
Affymetrix Gene-Chip Genotyping Analysis Software
(GTYPE) 4.1. Copy number analysis was performed
with Copy Number Analyzer for Affymetrix Gene-
Chip arrays (CNAG 3.0), as described before.28
Statistical Analysis
Where appropriate, w2-test/Fisher’s exact test or
nonparametric tests (Mann–Whitney U-test) were
used for comparisons of the groups. Spearman’s
correlation rank was applied for the correlation
between the variables. All statistical analysis was
carried out using the Statistical Package for the
Social Sciences version 17.0 (SPSS, Chicago, IL,
USA). P-values ofo0.05 were considered significant.
Results
Classification and Steroid Receptor Profile of
Apocrine Carcinomas
Morphologically, all 55 cases fulfilled the criteria for
apocrine carcinoma and were characterized by large
cells with prominent eosinophilic, flocculent cyto-
plasm, sharp cell borders and large nuclei with
prominent macronucleoli (Figures 1a and b). Of
these, 38 cases (69%) also fulfilled immunopheno-
typic diagnostic requirements for pure apocrine
carcinoma: ER and PR negative, AR positive
(Figures 1c and e, Table 1). The 17 remaining cases
(31%) were then termed ‘apocrine-like’ carcinomas
because they lacked the specific apocrine immuno-
phenotypic profile (Figures 1d and f). These were
further subcharacterized as apocrine-like carcinomas
with ERþ /AR immunophenotype (three cases),
apocrine-like carcinomas with ER/AR immunophe-
notype (four cases) and apocrine-like carcinomas with
ERþ /ARþ immunophenotype (10 cases) (Table 1).
The mean tumor AR positivity was significantly
higher in the pure apocrine carcinoma subgroup in
comparison with the apocrine-like carcinoma ARþ /ER
þ subgroup (76 vs 59%, P¼ 0.037). Pure apocrine
carcinomas exhibited a diffuse and strong nuclear
staining of AR (16 of 30 or 53% of pure apocrine
carcinomas had a 100% cells expressing AR). In
contrast, none of the 17 apocrine-like carcinoma cases
exhibited such complete AR expression.
HER-2/neu Expression in Apocrine Carcinomas
Her-2/neu protein overexpression (score 3þ ) was
observed in 54% of the cases in the entire cohort
without significant difference between the pure
apocrine carcinoma and apocrine-like carcinoma
groups (57 vs 47%, P¼ 0.81) (Figure 1g).
HER-2/neu gene amplification was detected in 28
of 54 tested cases (52%) without significant differ-
ences between the pure apocrine carcinoma and the
apocrine-like carcinoma group (54 vs 46%, P¼ 0.42)
(Figure 2a). The average HER-2/neu gene signal
number per cell ranged from 1.67 to 50 (mean: 9.57).
HER-2/neu FISH results were concordant with
Her-2/neu immunohistochemistry results in 49 of
53 available cases (92%). Four positive immunohis-
tochemistry Her-2/neu results (score 3þ ) were
discordant with HER-2 FISH results (negative for
HER-2/neu gene amplification). Three of eight cases
(38%) with equivocal immunohistochemistry (score
2þ ) had HER-2/neu gene amplification.
Figure 1 (a and b) Hematoxylin and eosin -stained sections of two cases of breast carcinomas with apocrine features: pure apocrine
carcinoma (a) and apocrine-like carcinoma (b) (40 magnification). (c and d) Immunohistochemistry showing negative estrogen receptor
expression in a case of pure apocrine carcinoma with a positive staining of normal epithelium (c), and strongly positive expression in an
apocrine-like breast carcinoma (d) (10 magnification). (e and f) Immunohistochemistry showing diffusely positive androgen receptor
expression in a case of a pure apocrine carcinoma (e), and negative expression in an apocrine-like carcinoma (f) ( 20 magnification).
(g and h) Immunohistochemistry showing strong membrane expression of EGFR protein in a case of pure apocrine carcinoma (g), and 3þ
membrane expression of Her-2/neu protein in a case of apocrine-like breast carcinoma (h) (20 magnification).
EGFR and HER-2/neu in apocrine carcinoma
646 S Vranic et al
Modern Pathology (2010) 23, 644–653
EGFR and HER-2/neu in apocrine carcinoma
S Vranic et al 647
Modern Pathology (2010) 23, 644–653
Six samples had fewer HER-2/neu signals per cell
than signals for chromosome 17 centromere (ratio:
0.72–0.99). One of these cases had a Her-2/neu
protein overexpression.
Polysomy of chromosome 17 (defined as three
or more copies of CEP17 signals per nucleus) was
observed in 10 pure apocrine carcinomas (32%)
and 8 apocrine-like carcinomas (50%). Polysomy
17 was seen without HER-2/neu gene amplification
in 8 cases (Figure 2c) and with HER-2/neu gene
amplification in 10 cases. The polysomy 17 rate was
low: mean 3.55 CEP17 signals; (range: 3.0–6.0). Two
pure apocrine carcinomas and three apocrine-like
carcinomas (5 of 8, 63%) with polysomy 17 alone
had Her-2/neu protein expression scores of 2 to 3þ
by immunohistochemistry.
EGFR Expression in Apocrine Carcinomas
In all, 34 out of 55 (62%) cases expressed EGFR
protein (scores 1 to 3þ ). A significantly higher pro-
portion of pure apocrine carcinomas was positive for
EGFR protein in comparison with the apocrine-like
carcinoma subgroups (76 vs 29%, P¼ 0.006) (Figure
1h). A diffuse (450% of positive cells) and strong
(intensity scores 2 to 3þ ) EGFR expression was seen
in 20 of 29 (69%) of the pure apocrine carcinoma-
positive cases and in 5 out of 5 (100%) of the
apocrine-like carcinoma-positive cases.
EGFR gene amplification was a rare event present
only in three (two pure apocrine and one apocrine-
like tumors) of 44 studied cases (7%) (Figure 2b). All
three cases exhibited EGFR protein overexpression.
The average EGFR gene signal number per cell
ranged from 1.6 to 20 (mean: 5.76).
Polysomy of chromosome 7 (defined as three or
more copies of CEP7 signals per nucleus) was
detected in 20 of 33 pure apocrine carcinomas
(61%) and in 3 of 11 apocrine-like carcinomas
(27%) either alone (21 cases) (Figure 2d) or in
association with the EGFR gene amplification (two
cases). Polysomy 7 was more frequently observed in
the pure apocrine carcinoma subgroup compared with
Table 1 Status of EGFR and Her-2/neu protein expression and gene amplification in pure apocrine carcinomas and subgroups of
apocrine-like carcinomas
Category Androgen r
eceptor (AR)a
Her-2/neub HER-2/neu
(FISH)c
EGFRd EGFR
(FISH)c
Pure apocrine carcinomas 38/38 (100%)
Mean: 76
Range: 10–100
21/37 (57%) 20/37 (54%) 29/38 (76%) 2/35 (6%)
Apocrine-like carcinomas (ER+, AR+) 10/10 (100%)
Mean: 59
Range: 15–90
2/10 (20%) 4/10 (40%) 3/10 (30%) 1/7 (14%)
Apocrine-like carcinomas (ER+, AR) 0/3 (0%) 3/3 (100%) 3/3 (100%) 0/3 (0%) 0/1 (0%)
Apocrine-like carcinomas (ER, AR) 0/4 (0%) 3/4 (75%) 1/4 (25%) 2/4 (50%) 0/4 (0%)
a
Positivity defined if 410% cells exhibited nuclear staining.
b
Defined by the 3+ score by immunohistochemistry.
c
Defined by the gene to centromere ratio 42.2.
d
Scores 1 to 3+ by immunohistochemistry.
Figure 1 Continued.
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the apocrine-like carcinoma subgroup (P¼ 0.083).
Overall, the level of polysomy 7 was low (mean:
4.09, range: 3.0–7.06). A weak positive correlation
between polysomy 7 and the EGFR protein expression
was also present (P¼ 0.025, r¼ 0.326).
Chromosomal Analysis Using Conventional
Cytogenetics and SNP Array Assay
Corroborative genetic evidence for FISH results was
obtained in three cases, which were further studied
by conventional cytogenetics and SNP arrays. One
case of pure apocrine carcinoma (displaying
polysomy 7 (4.37 CEP7 copies on average) and
HER-2/neu gene amplification) was analyzed by
conventional cytogenetic analysis (see Acknowl-
edgement) and showed complex cytogenetic altera-
tions (Figure 3) described as: 65–69,XXX,þ i(1)(q10),
2,3,add(3)(p12),add(6) (q27),þ 7,8,10,11,add
(11)(p15),add(11)(q23),12,13,add(14)(p11.2),15,
þ16,17,18,19,add(19)(q13.4),520,21,22,
Figure 3 Metaphase FISH analysis of the apocrine carcinoma
showing amplification of the HER-2/neu gene (red). One of the
larger marker chromosomes contains homogeneously staining
region (hsr) of HER-2/neu gene amplification.
Figure 2 Pure apocrine carcinomas showing HER-2/neu gene amplification (a), EGFR gene amplification (b), polysomy 17 (CEP17)
without HER-2/neu gene amplification in a case of an apocrine-like carcinoma (average: 6.06 signals per cell) (c) and polysomy 7 (CEP7)
without EGFR gene amplification (average: 3.62 signals per cell) (d).
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þmar1,þmar2,þmar3,þmar4,þmar5,þ 5-8mar[5]/
130–138, idemx2[2]/46,XX[13]. Another two cases
(one pure apocrine carcinoma and one apocrine-like
carcinoma, both with HER-2/neu gene amplifica-
tion) were studied by SNP arrays, which confirmed
FISH results and further revealed amplification
of CEP17 without polysomy 17 in the first one,
whereas the second one (Sample GLID09_0050) had
coamplification of HER-2/neu and TOP2A along
with a gain of CEP17 (Figure 4).
Molecular Subclassification of Carcinomas with
Apocrine Morphology
We found a statistically significant inverse correla-
tion between EGFR and Her-2/neu expression in the
pure apocrine carcinoma subgroup (P¼ 0.006,
r¼0.499). Therefore, 20 of 37 (54%) pure apocrine
carcinoma cases can be classified as HER-2-over-
expressing, whereas the remaining 17 cases (46%)
as triple-negative breast carcinomas. In all, 16 out of
17 triple-negative pure apocrine carcinomas (94%)
overexpressed EGFR and would accordingly be clas-
sified as basal-like breast carcinomas29 (Table 2).
None of the pure apocrine carcinomas fulfilled the
criteria for luminal tumors.29–31
In contrast, a large proportion of apocrine-like
carcinomas belonged to the luminal group (13 of 17
cases, 76%). Only three cases (18%) could be classified
as triple-negative breast carcinomas and one case only
as HER-2-overexpressing breast carcinoma.
Discussion
The diagnosis of apocrine carcinoma of the breast
has been controversial because of the lack of strict
diagnostic criteria. With the increasing use of
immunohistochemistry, apocrine breast cancer dif-
ferentiation has shown a consistent pattern of
steroid receptor expression irrespective of grade8
and this method should be applied for unequivocal
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Figure 4 SNP array karyotypes of chromosome 17 for two samples with amplification of HER-2/neu. The first one (Sample GLID09_0048)
had amplification of both CEP17 and HER-2/neu amplification without polysomy 17, whereas the second one (Sample GLID09_0050) had
coamplification of HER-2/neu and TOP2A along with a gain of CEP17. Plots are as follows: (A) the raw log 2 ratio of tumor/normal for
each probe on the array; (B) smoothing average over 10 probes; and (C) Hidden Markov Model of copy number with aqua¼1, yellow¼2,
pink¼3, pink-red¼4, red-pink¼5 and red 45.
Table 2 Molecular subclassification of apocrine carcinoma
subtypes
Apocrine carcinoma subtype Molecular phenotype
Pure apocrine carcinoma HER-2 (20/37, 54%)a
Triple negative (17/37, 46%)
Basal-like breast carcinomab
(16/17, 94%)
Apocrine-like carcinoma Luminal (13/17, 76%)
Triple negative (3/17, 18%)
Basal-like breast carcinomab
(2/3, 67%)
HER-2 (1/17, 6%)
a
HER-2/neu gene amplification was used as a criterion.
b
On the basis of EGFR protein expression (Nielsen et al29).
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definition of this special carcinoma type. With such
consistency, additional correlations between the
histological phenotype and biological potential
become more meaningful.
In this study, we applied strict morphological and
immunohistochemical criteria to correctly classify
and characterize apocrine carcinoma of the breast.
Consequently, our results clearly separated breast
tumors with apocrine cytomorphology into two
different groups: the pure apocrine carcinomas with
consistent lack of ER and overexpression of AR, and
morphologically apocrine-like carcinomas that did
not exhibit the protein expression profile associated
with the true apocrine phenotype.4,5,13,32 Similarly,
Celis et al8 using another set of morphological
and immunohistochemical criteria for classification
of apocrine carcinoma defined and confirmed the
existence of a distinct apocrine carcinoma group
with a consistent steroid receptor profile (ER,
ARþ ). Together, these results strongly support the
recent advances in molecular classification of breast
carcinoma that have revealed the existence of a
specific ‘molecular apocrine’ gene expression pro-
file among ER-negative breast carcinomas character-
ized primarily by increased AR signaling, along with
a common Her-2/neu gene amplification.13 The pure
apocrine carcinoma subgroup from our study seems
to be equivalent to the ‘molecular apocrine’ group
from Farmers’ study although that cohort was not
entirely compatible with pure apocrine carcino-
mas.13 Our findings showing coexpression of AR
and Her-2/neu proteins in pure apocrine carcinomas
also support results of other studies that highlighted
a functional cross-talk and association between AR
and HER-2/neu in a subset of breast carcinomas and
breast carcinoma cell lines.17,33
Pure apocrine carcinomas were further character-
ized by nearly mutually exclusive expression of Her-
2/neu and EGFR proteins. Thus, a majority of HER-
2-negative cases (that is, triple-negative apocrine
carcinomas) overexpressed EGFR and accordingly
could be classified as basal-like breast carcino-
mas.29–31 On the other hand, HER-2-overexpressing
pure apocrine carcinomas were mostly negative for
EGFR protein expression.
The apocrine-like carcinomas were much more
heterogeneous with various combinations of steroid
receptor expression including AR. Apocrine-
like carcinomas are characterized by a common ER
expression and HER-2/neu gene amplification but
significantly less common EGFR overexpression, thus
mainly belonging to the luminal phenotypes (A and B)
according to the molecular classification of breast
carcinomas.30,31 It is noteworthy that of the remaining
four ER-negative apocrine-like carcinomas, only one
case had HER-2/neu gene amplification.
Our results suggest that a strict definition of
pure apocrine carcinomas could clarify some of the
previous contradictions in the classification of
apocrine carcinoma (variable and heterogeneous
gene expression profiles of morphologically defined
apocrine tumors) leading some investigators to
challenge its existence.18
Overexpression of Her-2/neu protein has been
reported in up to 25% of invasive breast carcinomas
and has been associated with a worse clinical
outcome.34 In most cases, this can be attributed to
amplification of the HER-2/neu gene located on the
long arm of chromosome 17 (17q12).35 Our study
revealed HER-2/neu gene amplification inB52% of
the cases, similar to the rate of HER-2/neu gene
amplification in invasive apocrine carcinomas of
the breast observed in two previously published
small cohorts (44 and 50%, Moinfar et al12 and Varga
et al,36 respectively). The pure apocrine carcinoma
subgroup exhibited slightly higher rate of HER-2/
neu gene amplification in comparison with the
apocrine-like carcinoma subgroup, but the differ-
ence was not statistically significant. This is in line
with previous studies, which demonstrated a strong
association between HER-2/neu status and apocrine
differentiation.13,37 Although we found a high degree
of concordance between immunohistochemistry and
FISH results, four cases were negative for HER-2/neu
gene amplification despite high protein expression on
immunohistochemistry, which was previously ex-
plained by various preanalytical and analytical factors
including tissue fixation, a choice of the anti-Her-2/
neu antibody and scoring system.37,38
Aneusomy 17, including polysomy 17, has been a
common observation in breast carcinomas,39,40
although the definition of polysomy 17 is not
universally defined.24 Therefore, we followed the
arbitrary cutoff of three or more copies of CEP17
applied in previous publications.22,25,26 Our FISH
analysis revealed polysomy 17 in a proportion of
apocrine carcinomas, either as the sole finding or in
combination with HER-2/neu gene amplification.
CEP17 polysomy without concomitant HER-2/neu
gene amplification was seen in eight cases of which
five had Her-2/neu protein overexpression (scores
2þ and 3þ ). Several investigators previously con-
sidered polysomy 17 a potential cause of equivocal
HER-2/neu results by FISH or immunohistochem-
istry.25 However, Vanden Bempt et al22 found neither
increased Her-2/neu protein nor increased HER-2
mRNA in polysomy 17 cases and concluded that the
tumors displaying unamplified polysomy 17 prob-
ably represented more Her-2/neu-negative than Her-
2/neu-positive breast tumors. Some investigators
recently questioned the interpretation of the CEP17
copy number as a reliable predictor of the entire
chromosome 17 polysomy,41 and our whole genome
analysis using SNP arrays in two cases also supports
this observation.
EGFR is a 170-kDa transmembrane glycoprotein
encoded by the HER-1 protooncogene, located at
7p11.2-p12.42 High expression of EGFR in a variety
of epithelial tumors has led to the development of a
number of drugs specifically targeting the EGFR that
are now in use for treatment of advanced colorectal
carcinoma, non-small cell lung carcinoma, head and
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neck squamous cell carcinoma and pancreatic
carcinoma.43 EGFR protein expression has also been
a common finding in breast carcinoma, particularly
in a subgroup of triple-negative, basal-like breast
carcinomas (450%) leading some investigators to
use it as a surrogate marker for a basal-like breast
carcinoma.29 However, EGFR gene alterations (acti-
vating mutations and gene amplification) tend to be
a rare event in breast carcinoma and were found in
o8% of the cases.44,45 In this study, we demon-
strated EGFR protein expression in 62% of the cases.
The expression pattern was predominantly strong
(scores 2 to 3þ ) and diffuse (450% of positive
cells) in both subgroups and was not accompanied
by the EGFR gene amplification, similar to the
results of a study by Park et al.45 Polysomy of
chromosome 7 (CEP7), which we found associated
with the pure apocrine carcinoma subgroup, is a
novel finding, not previously associated with apoc-
rine breast cancer.46–49 It also correlated and might
be responsible for the EGFR protein overexpression
in the pure apocrine carcinoma.
In summary, our study indicates that breast
carcinomas with apocrine differentiation are
heterogeneous in molecular terms. The combina-
tion of morphological and immunohistochemical
criteria are essential for the proper identification
of pure apocrine carcinomas. When strictly de-
fined, these carcinomas express either Her-2/neu
or EGFR in a nearly exclusive manner, resulting in
their classification as either HER-2-overexpres-
sing or triple-negative types of breast carcinomas.
In contrast, apocrine-like carcinomas predomi-
nantly belong to the luminal molecular phenotype
(both A and B). Our findings also demonstrate
that EGFR and HER-2/neu have important roles in
the pathogenesis of apocrine carcinomas and
these findings may have significant therapeutic
implications.
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